Bristol-Myers Squibb (BMY) 10-Q 27 Oct 15 2015 Q3 Quarterly report Financial data

Document and Entity Information

Document and Entity Information	9 Months Ended
	Sep. 30, 2015shares
Document and Entity Information [Abstract]
Entity Registrant Name	BRISTOL MYERS SQUIBB CO
Entity Central Index Key	14,272
Entity Well-known Seasoned Issuer	Yes
Entity Current Reporting Status	Yes
Entity Voluntary Filers	No
Entity Filer Category	Large Accelerated Filer
Entity Common Stock, Shares Outstanding	1,668,286,317
Document Type	10-Q
Document Period End Date	Sep. 30, 2015
Document Fiscal Year Focus	2,015
Document Fiscal Period Focus	Q3
Current Fiscal Year End Date	--12-31
Amendment Flag	false

CONSOLIDATED STATEMENTS OF EARN

CONSOLIDATED STATEMENTS OF EARNINGS (UNAUDITED) - USD ($) $ in Millions	3 Months Ended		9 Months Ended
	Sep. 30, 2015	Sep. 30, 2014	Sep. 30, 2015	Sep. 30, 2014
Income Statement [Abstract]
Net product sales	$ 3,552	$ 2,843	$ 10,183	$ 8,420
Alliance and other revenues	517	1,078	2,090	3,201
Total revenues	4,069	3,921	12,273	11,621
Cost of products sold	1,097	1,007	2,957	2,966
Marketing, selling and administrative	983	1,029	2,845	2,937
Advertising and product promotion	193	171	495	521
Research and development	1,132	983	4,004	3,345
Other (income)/expense	(323)	(277)	(515)	(589)
Total Expenses	3,082	2,913	9,786	9,180
Earnings Before Income Taxes	987	1,008	2,487	2,441
Provision for Income Taxes	257	276	668	439
Net Earnings	730	732	1,819	2,002
Net Earnings Attributable to Noncontrolling Interest	24	11	57	11
Net Earnings Attributable to BMS	$ 706	$ 721	$ 1,762	$ 1,991
Earnings per Common Share
Basic	$ 0.42	$ 0.43	$ 1.06	$ 1.20
Diluted	0.42	0.43	1.05	1.19
Cash dividends declared per common share	$ 0.37	$ 0.36	$ 1.11	$ 1.08

CONSOLIDATED STATEMENTS OF COMP

CONSOLIDATED STATEMENTS OF COMPREHENSIVE INCOME (UNAUDITED) - USD ($) $ in Millions	3 Months Ended		9 Months Ended
	Sep. 30, 2015	Sep. 30, 2014	Sep. 30, 2015	Sep. 30, 2014
COMPREHENSIVE INCOME
Net Earnings	$ 730	$ 732	$ 1,819	$ 2,002
Other Comprehensive Income/(Loss), net of taxes and reclassifications to earnings [Abstract]
Derivatives qualifying as cash flow hedges	(46)	57	(49)	49
Pension and postretirement benefits	(131)	(407)	131	(508)
Available-for-sale securities	(16)	(22)	(22)	(7)
Foreign currency translation	(29)	(8)	(30)	2
Other Comprehensive Income/(Loss)	(222)	(380)	30	(464)
Comprehensive Income	508	352	1,849	1,538
Comprehensive Income Attributable to Noncontrolling Interest	24	11	57	11
Comprehensive Income Attributable to BMS	$ 484	$ 341	$ 1,792	$ 1,527

CONSOLIDATED BALANCE SHEETS (UN

CONSOLIDATED BALANCE SHEETS (UNAUDITED) - USD ($) $ in Millions	Sep. 30, 2015	Dec. 31, 2014
Current Assets:
Cash and cash equivalents	$ 3,975	$ 5,571
Marketable Securities, Current	1,438	1,864
Receivables	3,908	3,390
Inventories	1,130	1,560
Deferred income taxes	1,731	1,644
Prepaid expenses and other	529	470
Assets held-for-sale, Current	215	109
Total Current Assets	12,926	14,608
Property, plant and equipment	4,249	4,417
Goodwill	6,952	7,027
Other intangible assets	1,544	1,753
Deferred income taxes	719	915
Marketable Securities, Noncurrent	4,627	4,408
Other assets	762	621
Total Assets	31,779	33,749
Current Liabilities:
Short-term borrowings	642	590
Accounts payable	1,249	2,487
Accrued expenses	2,330	2,459
Deferred income	963	1,167
Accrued rebates and returns	1,159	851
Income taxes payable	179	262
Dividends payable	636	645
Total Current Liabilities	7,158	8,461
Pension, postretirement and postemployment liabilities	902	1,115
Deferred income	630	770
Income taxes payable	716	560
Other liabilities	468	618
Long-term debt	6,632	7,242
Total Liabilities	$ 16,506	$ 18,766
Commitments and contingencies (Note 19)
Bristol-Myers Squibb Company Shareholders' Equity:
Preferred stock, $2 convertible series, par value $1 per share: Authorized 10 million shares; issued and outstanding 4,178 in 2015 and 4,212 in 2014, liquidation value of $50 per share	$ 0	$ 0
Common stock, par value of $0.10 per share: Authorized 4.5 billion shares; 2.2 billion issued in both 2015 and 2014	221	221
Capital in excess of par value of stock	1,413	1,507
Accumulated other comprehensive loss	(2,395)	(2,425)
Retained earnings	32,446	32,541
Less cost of treasury stock - 540 million common shares in 2015 and 547 million in 2014	(16,606)	(16,992)
Total Bristol-Myers Squibb Company Shareholders' Equity	15,079	14,852
Noncontrolling interest	194	131
Total Equity	15,273	14,983
Total Liabilities and Equity	$ 31,779	$ 33,749

CONSOLIDATED BALANCE SHEETS (U5

CONSOLIDATED BALANCE SHEETS (UNAUDITED) (Parenthetical) - $ / shares	Sep. 30, 2015	Dec. 31, 2014
Statement of Financial Position [Abstract]
Preferred stock, $2 convertible series, par value	$ 1
Preferred stock, $2 convertible series, shares authorized	10,000,000
Preferred stock, $2 convertible series, shares issued	4,178	4,212
Preferred stock, $2 convertible series, shares outstanding	4,178	4,212
Preferred stock, $2 convertible series, liquidation value, per share	$ 50
Common stock, par value	$ 0.1
Common stock, shares authorized	4,500,000,000
Common stock, shares issued	2,200,000,000	2,200,000,000
Treasury stock, shares	540,000,000	547,000,000

CONSOLIDATED STATEMENTS OF CASH

CONSOLIDATED STATEMENTS OF CASH FLOWS (UNAUDITED) - USD ($) $ in Millions	9 Months Ended
	Sep. 30, 2015	Sep. 30, 2014
Cash Flows From Operating Activities:
Net Earnings	$ 1,819	$ 2,002
Adjustments to reconcile net earnings to net cash provided by operating activities:
Net earnings attributable to noncontrolling interest	(57)	(11)
Depreciation and amortization, net	300	364
Deferred income taxes	51	(57)
Stock-based compensation	176	147
Impairment charges	24	386
Pension settlements and amortization	178	206
Other adjustments	306	(562)
Changes in operating assets and liabilities:
Receivables	(586)	26
Inventories	231	(162)
Accounts payable	(1,218)	63
Deferred income	153	404
Income taxes payable	77	82
Other changes	(233)	(312)
Net Cash Provided by Operating Activities	1,221	2,576
Cash Flows From Investing Activities:
Sale and maturities of marketable securities	2,449	2,771
Purchases of marketable securities	(2,283)	(4,811)
Additions to property, plant and equipment and capitalized software	(535)	(335)
Divestitures and other proceeds	673	3,453
Acquisitions and other payments	(892)	(213)
Net Cash Provided by/(Used in) Investing Activities	(588)	865
Cash Flows From Financing Activities:
Short-term borrowings, net	54	45
Issuance of long-term debt	1,268
Repayments of long-term debt	(1,957)	(676)
Interest rate swap contract terminations	(2)	(4)
Issuances of common stock	231	229
Dividends	(1,859)	(1,800)
Net Cash Used in Financing Activities	(2,265)	(2,206)
Effect of Exchange Rates on Cash and Cash Equivalents	36	30
Increase/(Decrease) in Cash and Cash Equivalents	(1,596)	1,265
Cash and Cash Equivalents at Beginning of Period	5,571	3,586
Cash and Cash Equivalents at End of Period	$ 3,975	$ 4,851

BASIS OF PRESENTATION

BASIS OF PRESENTATION	9 Months Ended
	Sep. 30, 2015
Organization, Consolidation and Presentation of Financial Statements [Abstract]
Basis Of Presentation [Text Block]	BASIS OF PRESENTATION AND RECENTLY ISSUED ACCOUNTING STANDARDS Bristol-Myers Squibb Company (which may be referred to as Bristol-Myers Squibb, BMS or the Company) prepared these unaudited consolidated financial statements following the requirements of the Securities and Exchange Commission (SEC) and United States (U.S.) generally accepted accounting principles (GAAP) for interim reporting. Under those rules, certain footnotes and other financial information that are normally required for annual financial statements can be condensed or omitted. The Company is responsible for the consolidated financial statements included in this Form 10-Q. These consolidated financial statements include all normal and recurring adjustments necessary for a fair presentation of the financial position at September 30, 2015 and December 31, 2014 , and the results of operations for the three and nine months ended September 30, 2015 and 2014 , and cash flows for the nine months ended September 30, 2015 and 2014 . All intercompany balances and transactions have been eliminated. These unaudited consolidated financial statements and the related notes should be read in conjunction with the audited consolidated financial statements for the year ended December 31, 2014 included in the Annual Report on Form 10-K (2014 Form 10-K). Revenues, expenses, assets and liabilities can vary during each quarter of the year. Accordingly, the results and trends in these unaudited consolidated financial statements may not be indicative of full year operating results. The preparation of financial statements requires the use of management estimates and assumptions. The most significant assumptions are employed in estimates used in determining the fair value and potential impairment of intangible assets; sales rebate and return accruals; legal contingencies; income taxes; estimated selling prices used in multiple element arrangements; and pension and postretirement benefits. Actual results may differ from estimated results. Certain prior period amounts were reclassified to conform to the current period presentation. Pension settlements and amortization previously presented in Other in the consolidated statements of cash flows are now presented separately. In April 2015, the Financial Accounting Standards Board (FASB) issued amended guidance on the presentation of debt issuance costs. The new guidance requires debt issuance costs to be presented as a reduction to the carrying value of debt in the balance sheet, consistent with debt discounts. The guidance becomes effective on January 1, 2016, with early adoption permitted on a retrospective basis. The adoption of this standard will not have a material impact on our consolidated financial statements. In May 2014, the FASB issued a new standard related to revenue recognition, which requires an entity to recognize the amount of revenue to which it expects to be entitled for the transfer of promised goods or services to customers. The new standard will replace most of the existing revenue recognition standards in U.S. GAAP when it becomes effective. In July 2015, the FASB decided to delay the effective date by one year to January 1, 2018. Early adoption is permitted no earlier than 2017. The new standard can be applied retrospectively to each prior reporting period presented or retrospectively with the cumulative effect of the change recognized at the date of the initial application in retained earnings. The Company is assessing the potential impact of the new standard on financial reporting and has not yet selected a transition method. In April 2014, the FASB issued amended guidance on the use and presentation of discontinued operations in an entity's consolidated financial statements. The new guidance restricts the presentation of discontinued operations to business circumstances when the disposal of business operations represents a strategic shift that has or will have a major effect on an entity's operations and financial results. The guidance became effective on January 1, 2015.

BUSINESS SEGMENT INFORMATION

BUSINESS SEGMENT INFORMATION	9 Months Ended
	Sep. 30, 2015
Segment Reporting [Abstract]
Business Segment Information [Text Block]	BUSINESS SEGMENT INFORMATION BMS operates in a single segment engaged in the discovery, development, licensing, manufacturing, marketing, distribution and sale of innovative medicines that help patients prevail over serious diseases. A global research and development organization and supply chain organization are responsible for the discovery, development, manufacturing and supply of products. Regional commercial organizations market, distribute and sell the products. The business is also supported by global corporate staff functions. Segment information is consistent with the financial information regularly reviewed by the chief executive officer for purposes of evaluating performance, allocating resources, setting incentive compensation targets, and planning and forecasting future periods. Product revenues were as follows: Three Months Ended September 30, Nine Months Ended September 30, Dollars in Millions 2015 2014 2015 2014 Virology Baraclude (entecavir) $ 320 $ 325 $ 1,003 $ 1,100 Hepatitis C Franchise (a) 402 49 1,145 49 Reyataz (atazanavir sulfate) Franchise 270 338 867 1,044 Sustiva (efavirenz) Franchise (b) 333 357 940 1,037 Oncology Erbitux* (cetuximab) 167 187 501 542 Opdivo (nivolumab) 305 1 467 1 Sprycel (dasatinib) 411 385 1,191 1,095 Yervoy (ipilimumab) 240 350 861 942 Neuroscience Abilify* (aripiprazole) (c) 46 449 707 1,544 Immunoscience Orencia (abatacept) 484 444 1,345 1,209 Cardiovascular Eliquis (apixaban) 466 216 1,258 493 Mature Products and All Other (d) 625 820 1,988 2,565 Total Revenues $ 4,069 $ 3,921 $ 12,273 $ 11,621 * Indicates brand names of products which are trademarks not owned or wholly owned by BMS. Specific trademark ownership information is included at the end of this quarterly report on Form 10-Q. (a) Includes Daklinza (daclatasvir) revenues of $330 million and $38 million for the three months ended September 30, 2015 and 2014, respectively, and $892 million and $38 million for the nine months ended September 30, 2015 and 2014, respectively. Additionally, includes Sunvepra (asunaprevir) revenues of $72 million and $11 million for the three months ended September 30, 2015 and 2014, respectively, and $253 million and $11 million for the nine months ended September 30, 2015 and 2014, respectively. (b) Includes alliance and other revenue of $296 million and $309 million for the three months ended September 30, 2015 and 2014, respectively, and $823 million and $894 million for the nine months ended September 30, 2015 and 2014, respectively. (c) Includes alliance and other revenue of $19 million and $410 million for the three months ended September 30, 2015 and 2014, respectively, and $597 million and $1,350 million for the nine months ended September 30, 2015 and 2014, respectively. BMS's U.S. commercialization rights to Abilify* expired on April 20, 2015. (d) Includes Diabetes Alliance revenues of $53 million and $42 million for the three months ended September 30, 2015 and 2014, respectively, and $171 million and $248 million for the nine months ended September 30, 2015 and 2014, respectively. See "—Note 3. Alliances" for further information on the diabetes business divestiture.

ALLIANCES AND COLLABORATIONS

ALLIANCES AND COLLABORATIONS	9 Months Ended
	Sep. 30, 2015
Organization, Consolidation and Presentation of Financial Statements [Abstract]
Alliances and Collaborations [Text Block]	ALLIANCES BMS enters into collaboration arrangements with third parties for the development and commercialization of certain products. Although each of these arrangements is unique in nature, both parties are active participants in the operating activities of the collaboration and are exposed to significant risks and rewards depending on the commercial success of the activities. BMS may either in-license intellectual property owned by the other party or out-license its intellectual property to the other party. These arrangements also typically include research, development, manufacturing, and/or commercial activities and can cover a single investigational compound or commercial product or multiple compounds and/or products in various life cycle stages. The rights and obligations of the parties can be global or limited to geographic regions. We refer to these collaborations as alliances and our partners as alliance partners. Several key products such as Abilify* , Orencia , Sprycel , Sustiva ( Atripla* ), Eliquis, Erbitux* and Opdivo , as well as products comprising the diabetes alliance discussed in the 2014 Form 10-K and certain mature and other brands are included in alliance arrangements. Selected financial information pertaining to our alliances was as follows, including net product sales when BMS is the principal in the third-party customer sale for products subject to the alliance. Expenses summarized below do not include all amounts attributed to the activities for the products in the alliance, but only the payments between the alliance partners or the related amortization if the payments were deferred or capitalized. Three Months Ended September 30, Nine Months Ended September 30, Dollars in Millions 2015 2014 2015 2014 Revenues from alliances: Net product sales $ 981 $ 816 $ 3,203 $ 2,493 Alliance and other revenues 496 958 2,003 2,909 Total Revenues $ 1,477 $ 1,774 $ 5,206 $ 5,402 Payments to/(from) alliance partners: Cost of products sold $ 445 $ 338 $ 1,257 $ 1,016 Marketing, selling and administrative (14 ) 31 (15 ) 34 Advertising and product promotion 18 6 41 73 Research and development 89 33 277 13 Other (income)/expense (173 ) (411 ) (622 ) (964 ) Noncontrolling interest, pre-tax 17 7 45 18 Selected Alliance Balance Sheet information: Dollars in Millions September 30, December 31, Receivables - from alliance partners $ 838 $ 888 Accounts payable - to alliance partners 446 1,479 Deferred income from alliances 1,495 1,493 BMS entered into certain licensing and alliance agreements in 2015 (including options to license or acquire the related assets) which individually did not materially impact the consolidated financial statements. Upfront payments for these new agreements charged to research and development expenses were $266 million during the nine months ended September 30, 2015 (including $86 million in the third quarter of 2015). The prior period amounts disclosed in research and development expenses for upfront payments to alliance partners were revised to include similar type of payments. Specific information pertaining to each of our significant alliances is discussed in our 2014 Form 10-K, including their nature and purpose, the significant rights and obligations of the parties, and specific accounting policy elections. Significant developments and updates related to alliances during the nine months ended September 30, 2015 are set forth below. AstraZeneca In February 2014, BMS and AstraZeneca terminated their alliance agreements and BMS sold to AstraZeneca substantially all of the diabetes business comprising the alliance. The divestiture included the shares of Amylin and the resulting transfer of its Ohio manufacturing facility; the intellectual property related to Onglyza* / Kombiglyze* and Farxiga* / Xigduo* (including BMS's interest in the out-licensing agreement for Onglyza* in Japan); and the purchase of BMS’s manufacturing facility located in Mount Vernon, Indiana in the third quarter of 2015. Amylin's portfolio of products included Bydureon* , Byetta* , Symlin* and Myalept*. Substantially all employees dedicated to the diabetes business were transferred to AstraZeneca. The sale of the business has been completed in all jurisdictions. The stock and asset purchase agreement contains multiple elements to be delivered subsequent to the closing of the transaction, including the China diabetes business that was part of the alliance (transferred during the third quarter of 2014), the Mount Vernon, Indiana manufacturing facility (transferred during the third quarter of 2015) and the activities under the development and supply agreements. Each of these elements was determined to have a standalone value. As a result, a portion of the consideration received at closing was allocated to the undelivered elements using the relative selling price method after determining the best estimated selling price for each element. The remaining amount of consideration was included in the calculation for the gain on sale of the diabetes business. Contingent milestone and royalty payments are similarly allocated among the underlying elements if and when the amounts are determined to be payable to BMS. Amounts allocated to the sale of the business are immediately recognized in the results of operations. Amounts allocated to the other elements are recognized in the results of operations only to the extent each element has been delivered. BMS received proceeds of $179 million in the third quarter of 2015 for the transfer of the Mount Vernon, Indiana manufacturing facility and related inventories resulting in a gain of $79 million for the amounts allocated to the delivered elements. In September 2015, BMS transferred a percentage of its future royalty rights on Amylin net product sales ( Bydureon* , Byetta* , Symlin* and Myalept*) in the U.S. to CPPIB Credit Europe S.A.R.L., a Luxembourg private limited liability company (CPPIB). The transferred rights represent approximately 70% of potential future royalties BMS is entitled to in 2019 to 2025. In exchange for the transfer, BMS will receive an additional tiered-based royalty on Amylin net product sales in the U.S. from CPPIB in 2016 through 2018, which will be included in other income when earned. Summarized financial information related to the AstraZeneca alliances was as follows: Three Months Ended September 30, Nine Months Ended September 30, Dollars in Millions 2015 2014 2015 2014 Revenues from AstraZeneca alliances: Net product sales $ — $ 2 $ 10 $ 163 Alliance and other revenues 53 40 161 85 Total Revenues $ 53 $ 42 $ 171 $ 248 Payments to/(from) AstraZeneca: Cost of products sold: Profit sharing $ — $ 1 $ — $ 78 Cost reimbursements to/(from) AstraZeneca recognized in: Cost of products sold — — — (9 ) Marketing, selling and administrative — — — (7 ) Advertising and product promotion — — — (4 ) Research and development — (1 ) — (10 ) Other (income)/expense: Amortization of deferred income (31 ) (23 ) (80 ) (57 ) Provision for restructuring — — — (2 ) Royalties (28 ) (46 ) (190 ) (184 ) Transitional services (3 ) (18 ) (8 ) (83 ) Gain on sale of business (79 ) (292 ) (83 ) (539 ) Selected Alliance Cash Flow information: Deferred income 23 19 32 308 Divestitures and other proceeds 251 208 349 3,415 Selected Alliance Balance Sheet information: Dollars in Millions September 30, December 31, Deferred income attributed to: Assets not yet transferred to AstraZeneca $ — $ 176 Services not yet performed for AstraZeneca 170 226 Otsuka As described in the 2014 Form 10-K, BMS receives a share of U.S. net sales of Abilify* based on a tiered structure and recognizes revenues based on the expected annual contractual share using a forecast of net sales for the year ( 50% in 2015 and 33% in 2014). BMS's U.S. commercialization rights to Abilify* expired on April 20, 2015. In February 2015, BMS terminated the co-promotion agreement with Otsuka Pharmaceutical Co., Ltd. (Otsuka) in Japan only with respect to Sprycel . The termination is not expected to have a material impact on future results. Lilly BMS had an Epidermal Growth Factor Receptor (EGFR) commercialization agreement with Eli Lilly and Company (Lilly) through Lilly’s subsidiary ImClone for the co-development and promotion of Erbitux * in the U.S., Canada and Japan. Under the EGFR agreement, both parties actively participated in a joint executive committee and various other operating committees and shared responsibilities for research and development using resources in their own infrastructures. With respect to Erbitux *, Lilly manufactured bulk requirements for cetuximab in its own facilities and filling and finishing was performed by a third party for which BMS had oversight responsibility. BMS had exclusive distribution rights in North America and was responsible for promotional efforts in North America although Lilly had the right to co-promote in the U.S. at their own expense. BMS was the principal in third-party customer sales in North America and paid Lilly a distribution fee for 39% of Erbitux * net sales in North America plus a share of certain royalties paid by Lilly. BMS’s rights and obligations with respect to the commercialization of Erbitux * in North America would have expired in September 2018. In October 2015, BMS transferred its rights to Erbitux* in North America to Lilly in exchange for future royalties as described below. The transferred rights include, but are not limited to, full commercialization and manufacturing responsibilities. The transaction will be accounted for as a business divestiture in the fourth quarter and result in a non-cash charge of approximately $170 million for intangible assets directly related to the business and an allocation of goodwill. BMS will receive royalties through September 2018, which will be included in other income when earned. The royalty rates applicable to North America are 38% on Erbitux* net sales up to $165 million in 2015, $650 million in 2016, $650 million in 2017 and $480 million in 2018, plus 20% on net sales in excess of those amounts in each of the respective years. BMS shared rights to Erbitux* in Japan under an agreement with Lilly and Merck KGaA and received 50% of the pre-tax profit from Merck KGaA’s net sales of Erbitux* in Japan which was further shared equally with Lilly. BMS transferred its co-commercialization rights in Japan to Merck KGaA in the second quarter of 2015 in exchange for future royalties through 2032 which is included in other income when earned. Pfizer As described in the 2014 Form 10-K, BMS has an alliance with Pfizer, Inc. (Pfizer) to co-develop and co-promote Eliquis in most countries on a worldwide basis. BMS transferred full commercialization rights to Pfizer in certain smaller markets effective in the third quarter of 2015 in order to simplify operations. BMS will supply the product to Pfizer at cost plus a percentage of the net sales to end-customers in these markets. This change in the alliance arrangement is not expected to impact our pre-tax income. BMS retained co-promotional rights in the U.S., significant markets in Europe, as well as Canada, Australia, China, Japan and South Korea. The Medicines Company As described in the 2014 Form 10-K, BMS had an alliance with The Medicines Company for Recothrom on a global basis. The Medicines Company exercised its option to acquire the business for $132 million , resulting in a gain of $59 million (including $35 million fair value of the option) in February 2015. Valeant As described in the 2014 Form 10-K, BMS had an alliance with Valeant Pharmaceuticals International, Inc. (Valeant) for certain mature brands in Europe. Valeant exercised its option to acquire the business for $61 million , resulting in a gain of $88 million (including $34 million fair value of the option) in January 2015. Reckitt As described in the 2014 Form 10-K, BMS has an alliance with Reckitt Benckiser Group plc (Reckitt) covering certain BMS over-the-counter products sold primarily in Mexico and Brazil. In July 2015, Reckitt notified BMS that it was exercising its option to acquire all remaining rights in such products for those markets, the related inventory and BMS's manufacturing facility located in Mexico at a price determined primarily based upon a multiple of sales from May 2014 through May 2016. The closing is expected to occur in May 2016 subject to obtaining customary regulatory approvals. During 2015, a $123 million credit was included in other income (including $87 million in the third quarter of 2015) to decrease the fair value of the option due to the strengthening of the U.S dollar against local currencies. The anticipated proceeds are expected to approximate the fair value of the assets to be transferred. Promedior In September 2015, BMS purchased a warrant that gives BMS the exclusive right to acquire Promedior, Inc. (Promedior), a biotechnology company whose lead asset, PRM-151, is being developed for the treatment of idiopathic pulmonary fibrosis (IPF) and myelofibrosis (MF). The warrant is exercisable upon completion of the IPF or MF Phase II clinical studies being conducted by Promedior, which is expected to occur in 2017. The upfront payment allocated to the warrant was $84 million and included in research and development expenses in the third quarter of 2015. The remaining $66 million of the $150 million upfront payment was allocated to Promedior’s obligation to complete the Phase II studies which will be amortized over the expected period of the Phase II studies. The allocation was determined using level 3 inputs. Following BMS's review of the Phase II clinical study results, if BMS elects to exercise the warrant it will be obligated to pay an additional $300 million (if based on the IPF study results) or $250 million (if based on the MF study results), plus additional aggregate consideration of up to $800 million for contingent development and regulatory approval milestone payments in the U.S. and Europe.

ACQUISITIONS AND OTHER DIVESTIT

ACQUISITIONS AND OTHER DIVESTITURES ACQUISITIONS AND OTHER DIVESTITURES	9 Months Ended
	Sep. 30, 2015
Business Combinations [Abstract]
Acquisitions and other divestitures [Text Block]	ACQUISITIONS AND OTHER DIVESTITURES In April 2015, BMS acquired all of the outstanding shares of Flexus Biosciences, Inc. (Flexus), a privately held biotechnology company focused on the discovery and development of novel anti-cancer therapeutics. The acquisition provides BMS with full rights to F001287, a preclinical small molecule IDO1-inhibitor targeted immunotherapy. In addition, BMS acquired Flexus' IDO/TDO discovery program which includes its IDO-selective, IDO/TDO dual and TDO-selective compounds. The consideration includes an upfront payment of $800 million (plus acquisition costs) and contingent development and regulatory milestone payments up to $450 million . No significant Flexus processes were acquired, therefore the transaction was accounted for as an asset acquisition because Flexus was determined not to be a business as that term is defined in ASC 805 - Business Combinations. The consideration was allocated to F001287 and the IDO/TDO discovery program resulting in $800 million of research and development expenses and to net operating losses and tax credit carryforwards resulting in $14 million of deferred tax assets. In addition to transactions discussed in "—Note 3 . Alliances", BMS divested the Ixempra* business and several other businesses or product lines in 2015. These transactions generated net proceeds of $121 million resulting in pre-tax gains of $136 million (including a $40 million deferred gain from 2014). Additional contingent proceeds will be recognized in earnings when received. Revenues and pre-tax earnings related to these businesses were not material.

ASSETS HELD-FOR-SALE ASSETS HEL

ASSETS HELD-FOR-SALE ASSETS HELD-FOR-SALE	9 Months Ended
	Sep. 30, 2015
ASSETS HELD-FOR-SALE [Abstract]
Disposal Groups, Including Discontinued Operations, Disclosure [Text Block]	ASSETS HELD-FOR-SALE Assets held-for-sale were related to the Erbitux* business in North America comprising an alliance with Lilly and the business comprising an alliance with Reckitt at September 30, 2015 and to the businesses comprising alliances with The Medicines Company and Valeant at December 31, 2014 . The allocation of goodwill was based on the relative fair value of the applicable businesses to the Company's reporting unit. The following table provides the assets classified as held-for-sale: Dollars in Millions September 30, 2015 December 31, 2014 Assets Inventories $ 20 $ 38 Property, plant and equipment 14 — Goodwill 66 19 Other intangible assets 126 52 Accrued rebates and returns (11 ) — Assets held-for-sale $ 215 $ 109

OTHER (INCOME)_EXPENSE

OTHER (INCOME)/EXPENSE	9 Months Ended
	Sep. 30, 2015
Other Nonoperating Income (Expense) [Abstract]
Other (Income)/Expense [Text Block]	OTHER (INCOME)/EXPENSE Three Months Ended September 30, Nine Months Ended September 30, Dollars in Millions 2015 2014 2015 2014 Interest expense $ 41 $ 50 $ 141 $ 150 Investment income (18 ) (20 ) (74 ) (71 ) Provision for restructuring 10 35 50 72 Litigation charges/(recoveries) (2 ) 10 14 19 Equity in net income of affiliates (19 ) (12 ) (67 ) (81 ) Out-licensed intangible asset impairment — 18 13 18 Gain on sale of product lines, businesses and assets (208 ) (315 ) (370 ) (567 ) Other alliance and licensing income (187 ) (102 ) (472 ) (354 ) Pension curtailments, settlements and special termination benefits 48 28 111 137 Loss on debt redemption — — 180 45 Other 12 31 (41 ) 43 Other (income)/expense $ (323 ) $ (277 ) $ (515 ) $ (589 )

RESTRUCTURING

RESTRUCTURING	9 Months Ended
	Sep. 30, 2015
Restructuring Charges [Abstract]
Restructuring [Text Block]	RESTRUCTURING The following is the provision for restructuring: Three Months Ended September 30, Nine Months Ended September 30, Dollars in Millions 2015 2014 2015 2014 Employee termination benefits $ 9 $ 34 $ 45 $ 68 Other exit costs 1 1 5 4 Provision for restructuring $ 10 $ 35 $ 50 $ 72 Restructuring charges included termination benefits for workforce reductions of manufacturing, selling, administrative, and research and development personnel across all geographic regions of approximately 60 and 360 for the three months ended September 30, 2015 and 2014 , respectively, and approximately 685 and 760 for the nine months ended September 30, 2015 and 2014 , respectively. Employee termination costs in the aggregate of approximately $100 million are expected to be incurred in 2015 primarily related to specialty care transformation initiatives designed to create a more simplified organization across all functions and geographic markets. Subject to local regulations, costs will not be recognized until completion of discussions with works councils. The following table represents the activity of employee termination and other exit cost liabilities: Dollars in Millions 2015 2014 Liability at January 1 $ 156 $ 102 Charges 55 79 Changes in estimates (5 ) (7 ) Provision for restructuring 50 72 Foreign currency translation (11 ) (1 ) Payments (100 ) (73 ) Liability at September 30 $ 95 $ 100

INCOME TAXES

INCOME TAXES	9 Months Ended
	Sep. 30, 2015
Income Tax Disclosure [Abstract]
Income Taxes [Text Block]	INCOME TAXES Three Months Ended September 30, Nine Months Ended September 30, Dollars in Millions 2015 2014 2015 2014 Earnings Before Income Taxes $ 987 $ 1,008 $ 2,487 $ 2,441 Provision for Income Taxes 257 276 668 439 Effective tax rate 26.0 % 27.4 % 26.9 % 18.0 % The effective tax rate is typically lower than the U.S. statutory rate of 35% primarily because of undistributed earnings of certain foreign subsidiaries that have been considered or are expected to be indefinitely reinvested offshore. These undistributed earnings primarily relate to operations in Switzerland, Ireland and Puerto Rico. If these undistributed earnings are repatriated to the U.S. in the future, or if it were determined that such earnings are to be remitted in the foreseeable future, additional tax provisions would be required. Reforms to U.S. tax laws related to foreign earnings have been proposed and if adopted, may increase taxes, which could reduce the results of operations and cash flows. BMS operates under a favorable tax grant in Puerto Rico not scheduled to expire prior to 2023. The effective tax rates were also impacted by discrete items, particularly research and development charges resulting from acquisitions not deductible for tax purposes including $800 million for Flexus in the second quarter of 2015 and $148 million for iPierian in the second quarter of 2014. Other discrete items include the tax impact resulting from several business divestitures in both periods, including the diabetes business in 2014. BMS is currently being audited by a number of tax authorities and significant disputes may arise related to issues such as transfer pricing, certain tax credits and the deductibility of certain expenses. BMS estimates that it is reasonably possible that the total amount of unrecognized tax benefits at September 30, 2015 could decrease in the range of approximately $280 million to $340 million in the next twelve months as a result of the settlement of certain tax audits and other events resulting in the payment of additional taxes, the adjustment of certain deferred taxes and/or the recognition of tax benefits. It is also reasonably possible that new issues will be raised by tax authorities which may require adjustments to the amount of unrecognized tax benefits; however, an estimate of such adjustments cannot reasonably be made at this time. BMS believes that it has adequately provided for all open tax years by tax jurisdiction.

EARNINGS_(LOSS) PER SHARE

EARNINGS/(LOSS) PER SHARE	9 Months Ended
	Sep. 30, 2015
Earnings Per Share [Abstract]
Earnings/(Loss) Per Share [Text Block]	EARNINGS PER SHARE Three Months Ended September 30, Nine Months Ended September 30, Amounts in Millions, Except Per Share Data 2015 2014 2015 2014 Net Earnings Attributable to BMS used for Basic and Diluted EPS Calculation $ 706 $ 721 $ 1,762 $ 1,991 Weighted-average common shares outstanding – basic 1,668 1,658 1,666 1,656 Contingently convertible debt common stock equivalents — 1 — 1 Incremental shares attributable to share-based compensation plans 10 11 11 11 Weighted-average common shares outstanding – diluted 1,678 1,670 1,677 1,668 Earnings per Common Share: Basic $ 0.42 $ 0.43 $ 1.06 $ 1.20 Diluted $ 0.42 $ 0.43 $ 1.05 $ 1.19

FINANCIAL INSTRUMENTS AND FAIR

FINANCIAL INSTRUMENTS AND FAIR VALUE MEASUREMENTS	9 Months Ended
	Sep. 30, 2015
Investments, Debt and Equity Securities [Abstract]
Financial Instruments [Text Block]	FINANCIAL INSTRUMENTS AND FAIR VALUE MEASUREMENTS Financial assets and liabilities measured at fair value on a recurring basis are summarized below: September 30, 2015 December 31, 2014 Dollars in Millions Level 1 Level 2 Level 3 Total Level 1 Level 2 Level 3 Total Cash and cash equivalents - Money market and other securities $ — $ 3,435 $ — $ 3,435 $ — $ 5,051 $ — $ 5,051 Marketable securities: Certificates of deposit — 263 — 263 — 896 — 896 Commercial paper — 100 — 100 — — — — Corporate debt securities — 5,591 — 5,591 — 5,259 — 5,259 Equity funds — 88 — 88 — 94 — 94 Fixed income funds — 11 — 11 — 11 — 11 Auction Rate Securities (ARS) — — 12 12 — — 12 12 Derivative assets: Interest rate swap contracts — 46 — 46 — 46 — 46 Forward starting interest rate swap contracts — 11 — 11 — — — — Foreign currency forward contracts — 59 — 59 — 118 — 118 Equity investments 68 — — 68 36 — — 36 Derivative liabilities: Interest rate swap contracts — — — — — (3 ) — (3 ) Forward starting interest rate swap contracts — (9 ) — (9 ) — — — — Foreign currency forward contracts — (9 ) — (9 ) — — — — Written option liabilities — — — — — — (198 ) (198 ) Contingent consideration liability — — (8 ) (8 ) — — (8 ) (8 ) As further described in "Note 10. Financial Instruments and Fair Value Measurements" in our 2014 Form 10-K, our fair value estimates use inputs that are either (1) quoted prices for identical assets or liabilities in active markets (Level 1 inputs), (2) observable prices for similar assets or liabilities in active markets or for identical or similar assets or liabilities in markets that are not active (Level 2 inputs) or (3) unobservable inputs (Level 3 inputs). The following table summarizes the activity for financial assets and liabilities utilizing Level 3 fair value measurements: 2015 2014 Dollars in Millions ARS Written option liabilities Contingent consideration liability ARS Written option liabilities Contingent consideration liability Fair value at January 1 $ 12 $ (198 ) $ (8 ) $ 12 $ (162 ) $ (8 ) Settlements and other — 75 — — — — Changes in fair value — 123 — — (36 ) — Fair value at September 30 $ 12 $ — $ (8 ) $ 12 $ (198 ) $ (8 ) Available-for-sale Securities The following table summarizes available-for-sale securities: Dollars in Millions Amortized Gross Gross Fair Value September 30, 2015 Certificates of deposit $ 263 $ — $ — $ 263 Commercial paper 100 — — 100 Corporate debt securities 5,570 32 (11 ) 5,591 ARS 9 3 — 12 Equity investments 75 7 (14 ) 68 Total $ 6,017 $ 42 $ (25 ) $ 6,034 December 31, 2014 Certificates of deposit $ 896 $ — $ — $ 896 Corporate debt securities 5,237 30 (8 ) 5,259 ARS 9 3 — 12 Equity investments 14 22 — 36 Total $ 6,156 $ 55 $ (8 ) $ 6,203 Available-for-sale securities included in current marketable securities were $1,339 million as of September 30, 2015 and $1,759 million as of December 31, 2014 . As of September 30, 2015 , all non-current available-for-sale securities mature within five years, except for ARS. Equity investments of $68 million are included in other assets as of September 30, 2015 . Fair Value Option for Financial Assets Investments in equity and fixed income funds offsetting changes in fair value of certain employee retirement benefits were included in current marketable securities. Investment income resulting from the change in fair value for the investments in equity and fixed income funds was not significant. Qualifying Hedges The following table summarizes the fair value of outstanding derivatives: September 30, 2015 December 31, 2014 Dollars in Millions Balance Sheet Location Notional Fair Value Notional Fair Value Derivatives designated as hedging instruments: Interest rate swap contracts Other assets $ 1,750 $ 46 $ 847 $ 46 Interest rate swap contracts Other liabilities — — 1,050 (3 ) Forward starting interest rate swap contracts Other assets 500 11 — — Forward starting interest rate swap contracts Other liabilities 250 (9 ) — — Foreign currency forward contracts Prepaid expenses and other 766 47 1,323 106 Foreign currency forward contracts Other assets 60 12 100 12 Foreign currency forward contracts Accrued expenses 770 (9 ) — — Cash Flow Hedges — Foreign currency forward contracts are used to hedge forecasted intercompany inventory purchase transactions, primarily in non-U.S. markets, as well as hedge other foreign currency transactions. The effective portion of changes in fair value for contracts designated as cash flow hedges are temporarily reported in accumulated other comprehensive loss and included in earnings when the hedged item affects earnings. The net gains on foreign currency forward contracts are expected to be reclassified to net earnings (primarily included in cost of products sold) within the next two years. The notional amount of outstanding foreign currency forward contracts was primarily attributed to the euro ( $478 million ) and the Japanese yen ( $734 million ) at September 30, 2015 . The fair value of a foreign currency forward contract attributed to the Japanese yen (notional amount of $445 million ) not designated as a cash flow hedge was $2 million and was included in accrued expenses at September 30, 2015 . In 2015, BMS entered into $750 million of forward starting interest rate contracts maturing in March 2017 to hedge the variability of probable forecasted interest expense. The contracts are designated as cash flow hedges with the effective portion of fair value changes included in other comprehensive income. The earnings impact related to discontinued cash flow hedges and hedge ineffectiveness was not significant during the nine months ended September 30, 2015 and 2014 . Cash flow hedge accounting is discontinued when the forecasted transaction is no longer probable of occurring on the originally forecasted date, or 60 days thereafter, or when the hedge is no longer effective. Assessments to determine whether derivatives designated as qualifying hedges are highly effective in offsetting changes in the cash flows of hedged items are performed at inception and on a quarterly basis. Any ineffective portion of the change in fair value is included in current period earnings. Net Investment Hedges — Non-U.S. dollar borrowings of €950 million ( $1,064 million ) are designated to hedge the foreign currency exposures of the net investment in certain foreign affiliates. These borrowings are designated as net investment hedges and included in long-term debt. The effective portion of foreign exchange gains or losses on the remeasurement of the debt is included in the foreign currency translation component of accumulated other comprehensive loss with the related offset in long-term debt. Fair Value Hedges — Fixed-to-floating interest rate swap contracts are designated as fair value hedges and are used as part of an interest rate risk management strategy to create an appropriate balance of fixed and floating rate debt. The swaps and underlying debt for the benchmark risk being hedged are recorded at fair value. When the underlying swap is terminated prior to maturity, the fair value basis adjustment to the underlying debt instrument is amortized into earnings as an adjustment to interest expense over the remaining term of the debt. The notional amount of fixed-to-floating interest rate swap contracts terminated in 2015 was $147 million , generating proceeds of $28 million (including accrued interest of $1 million ). Additional contracts were terminated in connection with debt redemptions in 2015. Long-term debt includes: Dollars in Millions September 30, December 31, Principal Value $ 6,367 $ 6,804 Adjustments to Principal Value: Fair value of interest rate swap contracts 46 43 Unamortized basis adjustment from interest rate swap contract terminations 277 454 Unamortized bond discounts (58 ) (59 ) Total $ 6,632 $ 7,242 The fair value of debt was $6,935 million at September 30, 2015 and $8,045 million at December 31, 2014 and was valued using Level 2 inputs. Interest payments were $158 million and $131 million for the nine months ended September 30, 2015 and 2014 , respectively, net of amounts related to interest rate swap contracts. In May 2015, BMS issued senior unsecured notes in a registered public offering. The notes rank equally in right of payment with all of BMS's existing and future senior unsecured indebtedness. BMS may redeem the notes, in whole or in part, at any time at a predetermined redemption price. BMS also terminated forward starting interest rate swap contracts entered into during 2015, resulting in an unrealized loss in OCI. The following table summarizes the note issuances: Amounts in Millions Euro U.S. dollars Principal Value: 1.000% Euro Notes due 2025 € 575 $ 643 1.750% Euro Notes due 2035 575 643 Total € 1,150 $ 1,286 Proceeds net of discount and deferred loan issuance costs € 1,133 $ 1,268 Forward starting interest rate swap contracts terminated: Notional amount € 500 $ 559 Unrealized loss (16 ) (18 ) During the second quarter of 2015, the Company repurchased $500 million of long-term debt through a cash tender offer and redeemed €1.0 billion ( $1.1 billion ) of long-term debt following the issuance of new senior unsecured notes. In connection with the debt redemption activities, certain interest rate swap contracts were entered into and terminated during the second quarter of 2015. Debt redemption activity was as follows: Nine Months Ended September 30, Dollars in Millions 2015 2014 Principal amount $ 1,624 $ 582 Carrying value 1,795 633 Debt redemption price 1,957 676 Notional amount of interest rate swap contracts terminated 735 500 Interest rate swap contract termination payments 11 4 Loss on debt redemption (a) 180 45 (a) Including acceleration of debt issuance costs, loss on interest rate lock contract and other related fees.

RECEIVABLES

RECEIVABLES	9 Months Ended
	Sep. 30, 2015
Accounts Receivable, Net [Abstract]
Receivables [Text Block]	RECEIVABLES Dollars in Millions September 30, December 31, Trade receivables $ 2,844 $ 2,193 Less allowances (130 ) (93 ) Net trade receivables 2,714 2,100 Alliance receivables 838 888 Prepaid and refundable income taxes 175 178 Other 181 224 Receivables $ 3,908 $ 3,390 Non-U.S. receivables sold on a nonrecourse basis were $327 million and $684 million for the nine months ended September 30, 2015 and 2014 , respectively. Receivables from three pharmaceutical wholesalers in the U.S. aggregated 45% and 36% of total trade receivables at September 30, 2015 and December 31, 2014 .

INVENTORIES

INVENTORIES	9 Months Ended
	Sep. 30, 2015
Inventory, Net [Abstract]
Inventories [Text Block]	INVENTORIES Dollars in Millions September 30, December 31, Finished goods $ 355 $ 500 Work in process 561 856 Raw and packaging materials 214 204 Inventories $ 1,130 $ 1,560 Inventories expected to remain on-hand beyond one year (including $77 million for inventory pending regulatory approval) are included in other assets and were $277 million at September 30, 2015 and $232 million at December 31, 2014 .

PROPERTY, PLANT AND EQUIPMENT

PROPERTY, PLANT AND EQUIPMENT	9 Months Ended
	Sep. 30, 2015
Property, Plant and Equipment [Abstract]
Property, Plant and Equipment [Text Block]	PROPERTY, PLANT AND EQUIPMENT Dollars in Millions September 30, December 31, Land $ 107 $ 109 Buildings 4,442 4,830 Machinery, equipment and fixtures 3,313 3,774 Construction in progress 605 353 Gross property, plant and equipment 8,467 9,066 Less accumulated depreciation (4,218 ) (4,649 ) Property, plant and equipment $ 4,249 $ 4,417 The Mount Vernon, Indiana manufacturing facility was transferred to AstraZeneca in the third quarter of 2015 in connection with the sale of the diabetes business. The facility’s gross property, plant and equipment was $415 million on the date of transfer ( $182 million net of accumulated depreciation). See "—Note 3 . Alliances" for further discussion on the sale of the diabetes business. A fully depreciated bulk manufacturing facility ceased use in the third quarter of 2015 resulting in a $369 million reduction to gross property, plant and equipment and accumulated depreciation. Depreciation expense was $393 million and $412 million for the nine months ended September 30, 2015 and 2014 , respectively.

OTHER INTANGIBLE ASSETS

OTHER INTANGIBLE ASSETS	9 Months Ended
	Sep. 30, 2015
Goodwill and Intangible Assets Disclosure [Abstract]
Goodwill and Intangible Assets Disclosure [Text Block]	OTHER INTANGIBLE ASSETS Dollars in Millions September 30, December 31, Licenses $ 534 $ 1,090 Developed technology rights 2,357 2,358 Capitalized software 1,292 1,254 In-process research and development (IPRD) 280 280 Gross other intangible assets 4,463 4,982 Less accumulated amortization (2,919 ) (3,229 ) Total other intangible assets $ 1,544 $ 1,753 Licenses of $500 million ( $126 million net of accumulated amortization) were reclassified to assets held-for-sale during the second quarter of 2015 as a result of the expected transfer of the Erbitux* North American business to Lilly. See "—Note 5 . Assets Held-For-Sale" for further discussion. Amortization expense was $140 million and $222 million for the nine months ended September 30, 2015 and 2014 , respectively.

DEFERRED INCOME

DEFERRED INCOME	9 Months Ended
	Sep. 30, 2015
Deferred Revenue Disclosure [Abstract]
Deferred Revenue Disclosure [Text Block]	DEFERRED INCOME Dollars in Millions September 30, December 31, Alliances (Note 3) $ 1,495 $ 1,493 Gain on sale-leaseback transactions 31 45 Other 67 399 Total deferred income $ 1,593 $ 1,937 Current portion $ 963 $ 1,167 Non-current portion 630 770 Alliances include unamortized amounts for upfront, milestone and other licensing receipts, revenue deferrals attributed to the Gilead alliance and deferred income for the undelivered elements of the diabetes business divestiture. Other deferrals included $300 million invoiced for Daklinza under an early access program in France as of December 31, 2014, that was deferred until final pricing was obtained from the French government in the second quarter of 2015. Amortization of deferred income was $233 million and $270 million for the nine months ended September 30, 2015 and 2014 , respectively.

EQUITY

EQUITY	9 Months Ended
	Sep. 30, 2015
Equity [Abstract]
Stockholders' Equity Note Disclosure [Text Block]	EQUITY Common Stock Capital in Excess of Par Value of Stock Retained Earnings Treasury Stock Noncontrolling Interest Dollars and Shares in Millions Shares Par Value Shares Cost Balance at January 1, 2014 2,208 $ 221 $ 1,922 $ 32,952 559 $ (17,800 ) $ 82 Net earnings — — — 1,991 — — 11 Cash dividends declared — — — (1,796 ) — — — Employee stock compensation plans — — (407 ) — (9 ) 646 — Debt conversion — — (16 ) — (1 ) 35 — Distributions — — — — — — (35 ) Balance at September 30, 2014 2,208 $ 221 $ 1,499 $ 33,147 549 $ (17,119 ) $ 58 Balance at January 1, 2015 2,208 $ 221 $ 1,507 $ 32,541 547 $ (16,992 ) $ 131 Net earnings — — — 1,762 — — 73 Cash dividends declared — — — (1,857 ) — — — Employee stock compensation plans — — (94 ) — (7 ) 384 — Debt conversion — — — — — 2 — Distributions — — — — — — (10 ) Balance at September 30, 2015 2,208 $ 221 $ 1,413 $ 32,446 540 $ (16,606 ) $ 194 The components of other comprehensive income/(loss) were as follows: 2015 2014 Pretax Tax After tax Pretax Tax After tax Three Months Ended September 30, Derivatives qualifying as cash flow hedges: (a) Unrealized gains/(losses) $ (34 ) $ 14 $ (20 ) $ 96 $ (31 ) $ 65 Reclassified to net earnings (39 ) 13 (26 ) (13 ) 5 (8 ) Derivatives qualifying as cash flow hedges (73 ) 27 (46 ) 83 (26 ) 57 Pension and postretirement benefits: Actuarial losses (272 ) 96 (176 ) (679 ) 236 (443 ) Amortization (b) 20 (6 ) 14 26 (8 ) 18 Settlements (c) 48 (17 ) 31 28 (10 ) 18 Pension and postretirement benefits (204 ) 73 (131 ) (625 ) 218 (407 ) Available-for-sale securities (d) (24 ) 8 (16 ) (35 ) 13 (22 ) Foreign currency translation (34 ) 5 (29 ) (8 ) — (8 ) $ (335 ) $ 113 $ (222 ) $ (585 ) $ 205 $ (380 ) Nine Months Ended September 30, Derivatives qualifying as cash flow hedges: (a) Unrealized gains $ 36 $ (16 ) $ 20 $ 77 $ (25 ) $ 52 Reclassified to net earnings (102 ) 33 (69 ) (8 ) 5 (3 ) Derivatives qualifying as cash flow hedges (66 ) 17 (49 ) 69 (20 ) 49 Pension and postretirement benefits: Actuarial gains/(losses) 20 (7 ) 13 (978 ) 339 (639 ) Amortization (b) 67 (21 ) 46 79 (27 ) 52 Curtailments and settlements (c) 111 (39 ) 72 127 (48 ) 79 Pension and postretirement benefits 198 (67 ) 131 (772 ) 264 (508 ) Available-for-sale securities: Unrealized losses (31 ) 9 (22 ) (6 ) — (6 ) Realized gains — — — (1 ) — (1 ) Available-for-sale securities (31 ) 9 (22 ) (7 ) — (7 ) Foreign currency translation (14 ) (16 ) (30 ) 2 — 2 $ 87 $ (57 ) $ 30 $ (708 ) $ 244 $ (464 ) (a) Included in cost of products sold. (b) Included in cost of products sold, research and development, and marketing, selling and administrative expenses. (c) Included in other (income)/expense. (d) Includes unrealized losses only The accumulated balances related to each component of other comprehensive loss, net of taxes, were as follows: Dollars in Millions September 30, December 31, 2014 Derivatives qualifying as cash flow hedges $ 36 $ 85 Pension and other postretirement benefits (2,050 ) (2,181 ) Available-for-sale securities 9 31 Foreign currency translation (390 ) (360 ) Accumulated other comprehensive loss $ (2,395 ) $ (2,425 )

PENSION AND POSTRETIREMENT BENE

PENSION AND POSTRETIREMENT BENEFIT PLANS	9 Months Ended
	Sep. 30, 2015
Compensation and Retirement Disclosure [Abstract]
Pension and Other Postretirement Benefits [Text Block]	PENSION AND POSTRETIREMENT BENEFIT PLANS The net periodic benefit cost/(credit) of defined benefit pension and postretirement benefit plans includes: Three Months Ended September 30, Nine Months Ended September 30, Pension Benefits Other Benefits Pension Benefits Other Benefits Dollars in Millions 2015 2014 2015 2014 2015 2014 2015 2014 Service cost – benefits earned during the year $ 6 $ 10 $ 1 $ 1 $ 18 $ 30 $ 3 $ 3 Interest cost on projected benefit obligation 60 76 3 3 181 231 9 10 Expected return on plan assets (102 ) (131 ) (7 ) (7 ) (307 ) (395 ) (20 ) (21 ) Amortization of prior service credits — (1 ) (1 ) — (2 ) (3 ) (4 ) (1 ) Amortization of net actuarial (gain)/loss 20 29 1 (2 ) 70 85 3 (2 ) Curtailments and settlements 48 28 — — 111 127 — (3 ) Special termination benefits — — — — — 13 — — Net periodic benefit cost/(credit) $ 32 $ 11 $ (3 ) $ (5 ) $ 71 $ 88 $ (9 ) $ (14 ) Pension settlement charges were recognized after determining that the annual lump sum payments will likely exceed the annual interest and service costs for certain pension plans, including the primary U.S. pension plan. The charges included the acceleration of a portion of unrecognized actuarial losses. The applicable pension benefit obligation and pension plan assets were remeasured during 2015 resulting in a decrease to liabilities and a corresponding decrease in accumulated other comprehensive loss of $20 million . The changes resulted from a higher weighted average discount rate assumed in remeasuring the pension benefit obligations ( 4.2% at September 30, 2015 and 3.8% at December 31, 2014) partially offset by lower actual return on plan assets than expected. Contributions to the pension plans are expected to approximate $100 million during 2015 , of which $79 million occurred in the nine months ended September 30, 2015 . The expense attributed to defined contribution plans in the U.S. was $53 million and $45 million for the three months ended September 30, 2015 and 2014 , respectively, and $142 million and $141 million for the nine months ended September 30, 2015 , and 2014 , respectively.

EMPLOYEE STOCK BENEFIT PLANS

EMPLOYEE STOCK BENEFIT PLANS	9 Months Ended
	Sep. 30, 2015
Disclosure of Compensation Related Costs, Share-based Payments [Abstract]
Employee Stock Benefit Plans [Text Block]	EMPLOYEE STOCK BENEFIT PLANS Stock-based compensation expense was as follows: Three Months Ended September 30, Nine Months Ended September 30, Dollars in Millions 2015 2014 2015 2014 Restricted stock $ 20 $ 18 $ 62 $ 56 Market share units 9 9 27 25 Performance share units 34 21 87 66 Total stock-based compensation expense $ 63 $ 48 $ 176 $ 147 Income tax benefit $ 20 $ 16 $ 58 $ 49 In the nine months ended September 30, 2015 , 1.7 million restricted stock units, 0.7 million market share units and 1.6 million performance share units were granted. The weighted-average grant date fair value was $61.20 for restricted stock units, $67.03 for market share units and $65.07 for performance share units granted during the nine months ended September 30, 2015 . Substantially all restricted stock units vest ratably over a four year period. Market share units vest ratably over a four year period and the number of shares ultimately issued is based on share price performance. The fair value of market share units considers the probability of satisfying market conditions. Performance share units vest at the end of the three -year performance period. The number of shares issued when performance share units vest is determined based on the achievement of annual performance goals. The number of shares issued for 2014-2016 and 2015-2017 performance share unit awards are also adjusted based on the Company's three-year total shareholder return relative to a peer group of companies. Unrecognized compensation cost related to nonvested awards of $364 million is expected to be recognized over a weighted-average period of 2.4 years .

LEGAL PROCEEDINGS AND CONTINGEN

LEGAL PROCEEDINGS AND CONTINGENCIES	9 Months Ended
	Sep. 30, 2015
Commitments and Contingencies Disclosure [Abstract]
Legal Proceedings and Contingencies [Text Block]	LEGAL PROCEEDINGS AND CONTINGENCIES The Company and certain of its subsidiaries are involved in various lawsuits, claims, government investigations and other legal proceedings that arise in the ordinary course of business. The Company recognizes accruals for such contingencies when it is probable that a liability will be incurred and the amount of loss can be reasonably estimated. These matters involve patent infringement, antitrust, securities, pricing, sales and marketing practices, environmental, commercial, health and safety matters, consumer fraud, employment matters, product liability and insurance coverage. Legal proceedings that are material or that the Company believes could become material are described below. Although the Company believes it has substantial defenses in these matters, there can be no assurance that there will not be an increase in the scope of pending matters or that any future lawsuits, claims, government investigations or other legal proceedings will not be material. Unless otherwise noted, the Company is unable to assess the outcome of the respective litigation nor is it able to provide an estimated range of potential loss. Furthermore, failure to enforce our patent rights would likely result in substantial decreases in the respective product revenues from generic competition. INTELLECTUAL PROPERTY Baraclude — South Korea In 2013, DaeWoong Pharmaceutical Co. Ltd., Hanmi Pharmaceuticals Co., Ltd. Dong-A Pharmaceutical Co. Ltd. and other generic companies initiated separate invalidity actions in the Korean Intellectual Property Office against Korean Patent No. 160,523 (the ‘523 patent) covering the entecavir molecule. In January 2015, the Korean Intellectual Property Tribunal ruled that the '523 patent is valid and the decision was affirmed on appeal in September 2015 by the Patent Court. The ‘523 patent expired on October 9, 2015. Following the expiration of the ‘523 patent, generic companies have entered the South Korean market and we expect a significant decline in South Korean net product sales of Baraclude beginning in the fourth quarter of 2015. Net product sales of Baraclude in South Korea were $158 million in 2014 and $99 million for the nine months ended September 30, 2015. Plavix* — Australia As previously disclosed, Sanofi was notified that, in August 2007, GenRx Proprietary Limited (GenRx) obtained regulatory approval of an application for clopidogrel bisulfate 75mg tablets in Australia. GenRx, formerly a subsidiary of Apotex Inc. (Apotex), has since changed its name to Apotex. In August 2007, Apotex filed an application in the Federal Court of Australia (the Federal Court) seeking revocation of Sanofi’s Australian Patent No. 597784 (Case No. NSD 1639 of 2007). Sanofi filed counterclaims of infringement and sought an injunction. On September 21, 2007, the Federal Court granted Sanofi’s injunction. A subsidiary of the Company was subsequently added as a party to the proceedings. In February 2008, a second company, Spirit Pharmaceuticals Pty. Ltd., also filed a revocation suit against the same patent. This case was consolidated with the Apotex case and a trial occurred in April 2008. On August 12, 2008, the Federal Court of Australia held that claims of Patent No. 597784 covering clopidogrel bisulfate, hydrochloride, hydrobromide, and taurocholate salts were valid. The Federal Court also held that the process claims, pharmaceutical composition claims, and claim directed to clopidogrel and its pharmaceutically acceptable salts were invalid. The Company and Sanofi filed notices of appeal in the Full Court of the Federal Court of Australia (Full Court) appealing the holding of invalidity of the claim covering clopidogrel and its pharmaceutically acceptable salts, process claims, and pharmaceutical composition claims which have stayed the Federal Court’s ruling. Apotex filed a notice of appeal appealing the holding of validity of the clopidogrel bisulfate, hydrochloride, hydrobromide, and taurocholate claims. A hearing on the appeals occurred in February 2009. On September 29, 2009, the Full Court held all of the claims of Patent No. 597784 invalid. In November 2009, the Company and Sanofi applied to the High Court of Australia (High Court) for special leave to appeal the judgment of the Full Court. In March 2010, the High Court denied the Company and Sanofi’s request to hear the appeal of the Full Court decision. The case has been remanded to the Federal Court for further proceedings related to damages sought by Apotex. The Australian government has intervened in this matter and is also seeking damages for alleged losses experienced during the period when the injunction was in place. The Company and Apotex have settled the Apotex case and the case has been dismissed. The Australian government's claim is still pending. It is not possible at this time to predict the outcome of the Australian government’s claim or its impact on the Company. Eliquis - Inter-Partes Review (IPR) In August 2015, Bristol-Myers Squibb received a Petition for Inter Partes Review of U.S. Patent No. 6,967,208 (“the ‘208 patent”) that was filed at the United States Patent & Trademark Office by the Coalition for Affordable Drugs, which is affiliated with entities and individuals associated with a hedge fund. The ‘208 patent is a composition of matter patent that contains claims directed to apixaban, the active ingredient in Eliquis . The petition requests that the Patent Trial and Appeal Board (PTAB) initiate a proceeding to review the validity of the ‘208 patent, including claims that cover apixaban. The Company intends to respond to and oppose this petition in November 2015. The PTAB is expected to render a decision as to whether it will initiate this proceeding in February 2016. If the PTAB decides to initiate the proceeding, a decision on the merits would be expected by the first half of 2017. The Company intends to vigorously defend the ‘208 patent against this challenge. The ‘208 patent expires in February 2023; the Company has filed a request for patent term restoration with the U.S. Patent & Trademark Office requesting that the patent expiration date be restored to December 2026. PRICING, SALES AND PROMOTIONAL PRACTICES LITIGATION AND INVESTIGATIONS AWP Litigation As previously disclosed, the Company, together with a number of other pharmaceutical manufacturers, has been a defendant in a number of private class actions as well as suits brought by the attorneys general of various states. In these actions, plaintiffs allege that defendants caused the Average Wholesale Prices (AWPs) of their products to be inflated, thereby injuring government programs, entities and persons who reimbursed prescription drugs based on AWPs. The Company remains a defendant in two state attorneys general suits pending in state courts in Pennsylvania and Wisconsin. The Company has been designated as one of four defendants for separate trials in Wisconsin in 2016. Beginning in August 2010, the Company was the defendant in a trial in the Commonwealth Court of Pennsylvania (Commonwealth Court), brought by the Commonwealth of Pennsylvania. In September 2010, the jury issued a verdict for the Company, finding that the Company was not liable for fraudulent or negligent misrepresentation; however, the Commonwealth Court judge issued a decision on a Pennsylvania consumer protection claim that did not go to the jury, finding the Company liable for $28 million and enjoining the Company from contributing to the provision of inflated AWPs. The Company appealed the decision to the Pennsylvania Supreme Court and in June 2014, the Pennsylvania Supreme Court vacated the Commonwealth judge's decision and remanded the matter back to the Commonwealth Court. In January 2015, the Commonwealth Court entered judgment in favor of the Company. The Commonwealth of Pennsylvania has appealed this decision to the Pennsylvania Supreme Court. Qui Tam Litigation In March 2011, the Company was served with an unsealed qui tam complaint filed by three former sales representatives in California Superior Court, County of Los Angeles. The California Department of Insurance has elected to intervene in the lawsuit. The complaint alleges the Company paid kickbacks to California providers and pharmacies in violation of California Insurance Frauds Prevention Act, Cal. Ins. Code § 1871.7. It is not possible at this time to reasonably assess the outcome of this lawsuit or its impact on the Company. Plavix* State Attorneys General Lawsuits The Company and certain affiliates of Sanofi are defendants in consumer protection and/or false advertising actions brought by several states relating to the sales and promotion of Plavix* . It is not possible at this time to reasonably assess the outcome of these lawsuits or their potential impact on the Company. PRODUCT LIABILITY LITIGATION The Company is a party to various product liability lawsuits. Plaintiffs in these cases seek damages and other relief on various grounds for alleged personal injury and economic loss. As previously disclosed, in addition to lawsuits, the Company also faces unfiled claims involving its products. Plavix* As previously disclosed, the Company and certain affiliates of Sanofi are defendants in a number of individual lawsuits in various state and federal courts claiming personal injury damage allegedly sustained after using Plavix* . Currently, over 5,200 claims involving injury plaintiffs as well as claims by spouses and/or other beneficiaries, are filed in state and federal courts in various states including California, New Jersey, Delaware and New York. In February 2013, the Judicial Panel on Multidistrict Litigation granted the Company and Sanofi’s motion to establish a multidistrict litigation to coordinate Federal pretrial proceedings in Plavix* product liability and related cases in New Jersey Federal Court. It is not possible at this time to reasonably assess the outcome of these lawsuits or the potential impact on the Company. Reglan* The Company is one of a number of defendants in numerous lawsuits, on behalf of approximately 3,000 plaintiffs, including injury plaintiffs claiming personal injury allegedly sustained after using Reglan* or another brand of the generic drug metoclopramide, a product indicated for gastroesophageal reflux and certain other gastrointestinal disorders, as well as claims by spouses and/or other beneficiaries. The Company, through its generic subsidiary, Apothecon, Inc., distributed metoclopramide tablets manufactured by another party between 1996 and 2000. It is not possible at this time to reasonably assess the outcome of these lawsuits. The resolution of these pending lawsuits, however, is not expected to have a material impact on the Company. Byetta* Amylin, a former subsidiary of the Company, and Lilly are co-defendants in product liability litigation related to Byetta*. To date, there are over 500 separate lawsuits pending on behalf of over 2,400 active plaintiffs (including pending settlements), which include injury plaintiffs as well as claims by spouses and/or other beneficiaries, in various courts in the U.S. The Company has agreed in principle to resolve over 510 of these claims. The majority of these cases have been brought by individuals who allege personal injury sustained after using Byetta* , primarily pancreatic cancer and pancreatitis, and, in some cases, claiming alleged wrongful death. The majority of cases are pending in Federal Court in San Diego in a multidistrict litigation or in a coordinated proceeding in California Superior Court in Los Angeles. Amylin has product liability insurance covering a substantial number of claims involving Byetta* and any additional liability to Amylin with respect to Byetta* is expected to be shared between the Company and AstraZeneca. It is not possible to reasonably predict the outcome of any lawsuit, claim or proceeding or the potential impact on the Company. GOVERNMENT INVESTIGATIONS Like other pharmaceutical companies, the Company and certain of its subsidiaries are subject to extensive regulation by national, state and local government agencies in the U.S. and other countries in which BMS operates. As a result, the Company, from time to time is subject to various governmental inquiries and investigations. It is possible that criminal charges, substantial fines and/or civil penalties, could result from government investigations. The most significant investigations conducted by government agencies are listed below. Abilify* State Attorneys General Investigation In March 2009, the Company received a letter from the Delaware Attorney General’s Office advising of a multi-state coalition investigating whether certain Abilify* marketing practices violated those respective states’ consumer protection statutes. It is not possible at this time to reasonably assess the outcome of this investigation. FCPA Investigation In October 2015, the SEC approved a settlement that resulted in a resolution of the SEC's investigation of the Company under the Foreign Corrupt Practices Act (FCPA) relating to certain sales and marketing practices in China. The Company has signed a Cease and Desist Order and has agreed to a two-year self-monitoring period of reporting to the government and a payment of approximately $14.7 million in disgorgement, penalties and interest (accrued in prior quarters). The Company has also been advised by the Department of Justice that it has closed its inquiry into this matter. ENVIRONMENTAL PROCEEDINGS As previously reported, the Company is a party to several environmental proceedings and other matters, and is responsible under various state, federal and foreign laws, including the Comprehensive Environmental Response, Compensation and Liability Act (CERCLA), for certain costs of investigating and/or remediating contamination resulting from past industrial activity at the Company’s current or former sites or at waste disposal or reprocessing facilities operated by third parties. CERCLA Matters With respect to CERCLA matters for which the Company is responsible under various state, federal and foreign laws, the Company typically estimates potential costs based on information obtained from the U.S. Environmental Protection Agency, or counterpart state or foreign agency and/or studies prepared by independent consultants, including the total estimated costs for the site and the expected cost-sharing, if any, with other “potentially responsible parties,” and the Company accrues liabilities when they are probable and reasonably estimable. The Company estimated its share of future costs for these sites to be $61 million at September 30, 2015, which represents the sum of best estimates or, where no best estimate can reasonably be made, estimates of the minimal probable amount among a range of such costs (without taking into account any potential recoveries from other parties). North Brunswick Township Board of Education As previously disclosed, in October 2003, the Company was contacted by counsel representing the North Brunswick, NJ Board of Education (BOE) regarding a site where waste materials from E.R. Squibb and Sons may have been disposed from the 1940’s through the 1960’s. Fill material containing industrial waste and heavy metals in excess of residential standards was discovered during an expansion project at the North Brunswick Township High School, as well as at a number of neighboring residential properties and adjacent public park areas. In January 2004, the New Jersey Department of Environmental Protection (NJDEP) sent the Company and others an information request letter about possible waste disposal at the site, to which the Company responded in March 2004. The BOE and the Township, as the current owners of the school property and the park, are conducting and jointly financing soil remediation work and ground water investigation work under a work plan approved by the NJDEP, and have asked the Company to contribute to the cost. The Company is actively monitoring the clean-up project, including its costs. To date, neither the school board nor the Township has asserted any claim against the Company. Instead, the Company and the local entities have negotiated an agreement to attempt to resolve the matter by informal means, and avoid litigation. A central component of the agreement is the provision by the Company of interim funding to help defray cleanup costs and assure the work is not interrupted. The Company transmitted interim funding payments in December 2007 and November 2009. The parties commenced mediation in late 2008; however, those efforts were not successful and the parties moved to a binding allocation process. The parties are expected to conduct fact and expert discovery, followed by formal evidentiary hearings and written argument. In addition, in September 2009, the Township and BOE filed suits against several other parties alleged to have contributed waste materials to the site; that litigation has now been settled by the parties. The Company does not currently believe that it is responsible for any additional amounts beyond the two interim payments totaling $4 million already transmitted. Any additional possible loss is not expected to be material.

SUBSEQUENT EVENTS

SUBSEQUENT EVENTS	9 Months Ended
	Sep. 30, 2015
Subsequent Events [Abstract]
Subsequent Events [Text Block]	SUBSEQUENT EVENTS Five Prime In October 2015, BMS and Five Prime Therapeutics, Inc. (Five Prime) entered into an exclusive worldwide licensing and collaboration agreement for the development and commercialization of Five Prime’s colony stimulating factor 1 receptor (CSF1R) antibody program, including FPA008 currently in Phase I development for immunology and oncology indications. BMS will be responsible for the development, manufacturing and commercialization of FPA008, subject to Five Prime’s option to conduct certain studies at its cost to develop FPA008 in pigmented vilonodular synovitis (PVNS) and in combination with its own internal oncology pipeline assets. Five Prime also retained an option to co-promote in the U.S. The agreement replaces a previous clinical collaboration agreement between the two parties. The transaction is expected to close in the fourth quarter of 2015 upon obtaining customary regulatory approvals. In consideration for licensing rights, BMS will make an upfront payment of $350 million which will be included in research and development expense. BMS will also be committed to pay up to $1.4 billion upon the achievement of contingent development and regulatory milestones as well as future royalties if the product is approved and commercialized.

BASIS OF PRESENTATION (Policies

BASIS OF PRESENTATION (Policies)	9 Months Ended
	Sep. 30, 2015
Organization, Consolidation and Presentation of Financial Statements [Abstract]
New Accounting Pronouncements, Policy [Policy Text Block]	In April 2015, the Financial Accounting Standards Board (FASB) issued amended guidance on the presentation of debt issuance costs. The new guidance requires debt issuance costs to be presented as a reduction to the carrying value of debt in the balance sheet, consistent with debt discounts. The guidance becomes effective on January 1, 2016, with early adoption permitted on a retrospective basis. The adoption of this standard will not have a material impact on our consolidated financial statements. In May 2014, the FASB issued a new standard related to revenue recognition, which requires an entity to recognize the amount of revenue to which it expects to be entitled for the transfer of promised goods or services to customers. The new standard will replace most of the existing revenue recognition standards in U.S. GAAP when it becomes effective. In July 2015, the FASB decided to delay the effective date by one year to January 1, 2018. Early adoption is permitted no earlier than 2017. The new standard can be applied retrospectively to each prior reporting period presented or retrospectively with the cumulative effect of the change recognized at the date of the initial application in retained earnings. The Company is assessing the potential impact of the new standard on financial reporting and has not yet selected a transition method. In April 2014, the FASB issued amended guidance on the use and presentation of discontinued operations in an entity's consolidated financial statements. The new guidance restricts the presentation of discontinued operations to business circumstances when the disposal of business operations represents a strategic shift that has or will have a major effect on an entity's operations and financial results. The guidance became effective on January 1, 2015.

BUSINESS SEGMENT INFORMATION (T

BUSINESS SEGMENT INFORMATION (Tables)	9 Months Ended
	Sep. 30, 2015
Segment Reporting [Abstract]
Product Revenues [Table Text Block]	Product revenues were as follows: Three Months Ended September 30, Nine Months Ended September 30, Dollars in Millions 2015 2014 2015 2014 Virology Baraclude (entecavir) $ 320 $ 325 $ 1,003 $ 1,100 Hepatitis C Franchise (a) 402 49 1,145 49 Reyataz (atazanavir sulfate) Franchise 270 338 867 1,044 Sustiva (efavirenz) Franchise (b) 333 357 940 1,037 Oncology Erbitux* (cetuximab) 167 187 501 542 Opdivo (nivolumab) 305 1 467 1 Sprycel (dasatinib) 411 385 1,191 1,095 Yervoy (ipilimumab) 240 350 861 942 Neuroscience Abilify* (aripiprazole) (c) 46 449 707 1,544 Immunoscience Orencia (abatacept) 484 444 1,345 1,209 Cardiovascular Eliquis (apixaban) 466 216 1,258 493 Mature Products and All Other (d) 625 820 1,988 2,565 Total Revenues $ 4,069 $ 3,921 $ 12,273 $ 11,621 * Indicates brand names of products which are trademarks not owned or wholly owned by BMS. Specific trademark ownership information is included at the end of this quarterly report on Form 10-Q. (a) Includes Daklinza (daclatasvir) revenues of $330 million and $38 million for the three months ended September 30, 2015 and 2014, respectively, and $892 million and $38 million for the nine months ended September 30, 2015 and 2014, respectively. Additionally, includes Sunvepra (asunaprevir) revenues of $72 million and $11 million for the three months ended September 30, 2015 and 2014, respectively, and $253 million and $11 million for the nine months ended September 30, 2015 and 2014, respectively. (b) Includes alliance and other revenue of $296 million and $309 million for the three months ended September 30, 2015 and 2014, respectively, and $823 million and $894 million for the nine months ended September 30, 2015 and 2014, respectively. (c) Includes alliance and other revenue of $19 million and $410 million for the three months ended September 30, 2015 and 2014, respectively, and $597 million and $1,350 million for the nine months ended September 30, 2015 and 2014, respectively. BMS's U.S. commercialization rights to Abilify* expired on April 20, 2015. (d) Includes Diabetes Alliance revenues of $53 million and $42 million for the three months ended September 30, 2015 and 2014, respectively, and $171 million and $248 million for the nine months ended September 30, 2015 and 2014, respectively. See "—Note 3. Alliances" for further information on the diabetes business divestiture.

ALLIANCES AND COLLABORATIONS (T

ALLIANCES AND COLLABORATIONS (Tables)	9 Months Ended
	Sep. 30, 2015
Alliances and Collaborations Statement [Line Items]
Schedule of Collaborative Arrangements and Non-collaborative Arrangement Transactions [Table Text Block]	Selected financial information pertaining to our alliances was as follows, including net product sales when BMS is the principal in the third-party customer sale for products subject to the alliance. Expenses summarized below do not include all amounts attributed to the activities for the products in the alliance, but only the payments between the alliance partners or the related amortization if the payments were deferred or capitalized. Three Months Ended September 30, Nine Months Ended September 30, Dollars in Millions 2015 2014 2015 2014 Revenues from alliances: Net product sales $ 981 $ 816 $ 3,203 $ 2,493 Alliance and other revenues 496 958 2,003 2,909 Total Revenues $ 1,477 $ 1,774 $ 5,206 $ 5,402 Payments to/(from) alliance partners: Cost of products sold $ 445 $ 338 $ 1,257 $ 1,016 Marketing, selling and administrative (14 ) 31 (15 ) 34 Advertising and product promotion 18 6 41 73 Research and development 89 33 277 13 Other (income)/expense (173 ) (411 ) (622 ) (964 ) Noncontrolling interest, pre-tax 17 7 45 18 Selected Alliance Balance Sheet information: Dollars in Millions September 30, December 31, Receivables - from alliance partners $ 838 $ 888 Accounts payable - to alliance partners 446 1,479 Deferred income from alliances 1,495 1,493
AstraZeneca [Member]
Alliances and Collaborations Statement [Line Items]
Schedule of Collaborative Arrangements and Non-collaborative Arrangement Transactions [Table Text Block]	Summarized financial information related to the AstraZeneca alliances was as follows: Three Months Ended September 30, Nine Months Ended September 30, Dollars in Millions 2015 2014 2015 2014 Revenues from AstraZeneca alliances: Net product sales $ — $ 2 $ 10 $ 163 Alliance and other revenues 53 40 161 85 Total Revenues $ 53 $ 42 $ 171 $ 248 Payments to/(from) AstraZeneca: Cost of products sold: Profit sharing $ — $ 1 $ — $ 78 Cost reimbursements to/(from) AstraZeneca recognized in: Cost of products sold — — — (9 ) Marketing, selling and administrative — — — (7 ) Advertising and product promotion — — — (4 ) Research and development — (1 ) — (10 ) Other (income)/expense: Amortization of deferred income (31 ) (23 ) (80 ) (57 ) Provision for restructuring — — — (2 ) Royalties (28 ) (46 ) (190 ) (184 ) Transitional services (3 ) (18 ) (8 ) (83 ) Gain on sale of business (79 ) (292 ) (83 ) (539 ) Selected Alliance Cash Flow information: Deferred income 23 19 32 308 Divestitures and other proceeds 251 208 349 3,415 Selected Alliance Balance Sheet information: Dollars in Millions September 30, December 31, Deferred income attributed to: Assets not yet transferred to AstraZeneca $ — $ 176 Services not yet performed for AstraZeneca 170 226

ASSETS HELD-FOR-SALE ASSETS H30

ASSETS HELD-FOR-SALE ASSETS HELD-FOR-SALE (Tables)	9 Months Ended
	Sep. 30, 2015
ASSETS HELD-FOR-SALE [Abstract]
Disposal Groups, Including Discontinued Operations [Table Text Block]	The following table provides the assets classified as held-for-sale: Dollars in Millions September 30, 2015 December 31, 2014 Assets Inventories $ 20 $ 38 Property, plant and equipment 14 — Goodwill 66 19 Other intangible assets 126 52 Accrued rebates and returns (11 ) — Assets held-for-sale $ 215 $ 109

OTHER (INCOME)_EXPENSE (Tables)

OTHER (INCOME)/EXPENSE (Tables)	9 Months Ended
	Sep. 30, 2015
Other Nonoperating Income (Expense) [Abstract]
Schedule Of Other Income Expense [Table Text Block]	Three Months Ended September 30, Nine Months Ended September 30, Dollars in Millions 2015 2014 2015 2014 Interest expense $ 41 $ 50 $ 141 $ 150 Investment income (18 ) (20 ) (74 ) (71 ) Provision for restructuring 10 35 50 72 Litigation charges/(recoveries) (2 ) 10 14 19 Equity in net income of affiliates (19 ) (12 ) (67 ) (81 ) Out-licensed intangible asset impairment — 18 13 18 Gain on sale of product lines, businesses and assets (208 ) (315 ) (370 ) (567 ) Other alliance and licensing income (187 ) (102 ) (472 ) (354 ) Pension curtailments, settlements and special termination benefits 48 28 111 137 Loss on debt redemption — — 180 45 Other 12 31 (41 ) 43 Other (income)/expense $ (323 ) $ (277 ) $ (515 ) $ (589 )

RESTRUCTURING (Tables)

RESTRUCTURING (Tables)	9 Months Ended
	Sep. 30, 2015
Restructuring Charges [Abstract]
Schedule of Restructuring and Related Costs [Table Text Block]	The following is the provision for restructuring: Three Months Ended September 30, Nine Months Ended September 30, Dollars in Millions 2015 2014 2015 2014 Employee termination benefits $ 9 $ 34 $ 45 $ 68 Other exit costs 1 1 5 4 Provision for restructuring $ 10 $ 35 $ 50 $ 72
Schedule of Restructuring Reserve by Type of Cost [Table Text Block]	The following table represents the activity of employee termination and other exit cost liabilities: Dollars in Millions 2015 2014 Liability at January 1 $ 156 $ 102 Charges 55 79 Changes in estimates (5 ) (7 ) Provision for restructuring 50 72 Foreign currency translation (11 ) (1 ) Payments (100 ) (73 ) Liability at September 30 $ 95 $ 100

INCOME TAXES (Tables)

INCOME TAXES (Tables)	9 Months Ended
	Sep. 30, 2015
Income Tax Disclosure [Abstract]
Schedule Of Provision For Income Taxes [Table Text Block]	Three Months Ended September 30, Nine Months Ended September 30, Dollars in Millions 2015 2014 2015 2014 Earnings Before Income Taxes $ 987 $ 1,008 $ 2,487 $ 2,441 Provision for Income Taxes 257 276 668 439 Effective tax rate 26.0 % 27.4 % 26.9 % 18.0 %

EARNINGS_(LOSS) PER SHARE (Tabl

EARNINGS/(LOSS) PER SHARE (Tables)	9 Months Ended
	Sep. 30, 2015
Earnings Per Share [Abstract]
Schedule of Earnings/(Loss) Per Share, Basic and Diluted [Table Text Block]	Three Months Ended September 30, Nine Months Ended September 30, Amounts in Millions, Except Per Share Data 2015 2014 2015 2014 Net Earnings Attributable to BMS used for Basic and Diluted EPS Calculation $ 706 $ 721 $ 1,762 $ 1,991 Weighted-average common shares outstanding – basic 1,668 1,658 1,666 1,656 Contingently convertible debt common stock equivalents — 1 — 1 Incremental shares attributable to share-based compensation plans 10 11 11 11 Weighted-average common shares outstanding – diluted 1,678 1,670 1,677 1,668 Earnings per Common Share: Basic $ 0.42 $ 0.43 $ 1.06 $ 1.20 Diluted $ 0.42 $ 0.43 $ 1.05 $ 1.19

FINANCIAL INSTRUMENTS AND FAI35

FINANCIAL INSTRUMENTS AND FAIR VALUE MEASUREMENTS (Tables)	9 Months Ended
	Sep. 30, 2015
Investments, Debt and Equity Securities [Abstract]
Schedule of Fair Value, Assets and Liabilities Measured on Recurring Basis [Table Text Block]	Financial assets and liabilities measured at fair value on a recurring basis are summarized below: September 30, 2015 December 31, 2014 Dollars in Millions Level 1 Level 2 Level 3 Total Level 1 Level 2 Level 3 Total Cash and cash equivalents - Money market and other securities $ — $ 3,435 $ — $ 3,435 $ — $ 5,051 $ — $ 5,051 Marketable securities: Certificates of deposit — 263 — 263 — 896 — 896 Commercial paper — 100 — 100 — — — — Corporate debt securities — 5,591 — 5,591 — 5,259 — 5,259 Equity funds — 88 — 88 — 94 — 94 Fixed income funds — 11 — 11 — 11 — 11 Auction Rate Securities (ARS) — — 12 12 — — 12 12 Derivative assets: Interest rate swap contracts — 46 — 46 — 46 — 46 Forward starting interest rate swap contracts — 11 — 11 — — — — Foreign currency forward contracts — 59 — 59 — 118 — 118 Equity investments 68 — — 68 36 — — 36 Derivative liabilities: Interest rate swap contracts — — — — — (3 ) — (3 ) Forward starting interest rate swap contracts — (9 ) — (9 ) — — — — Foreign currency forward contracts — (9 ) — (9 ) — — — — Written option liabilities — — — — — — (198 ) (198 ) Contingent consideration liability — — (8 ) (8 ) — — (8 ) (8 )
Fair Value, Assets Measured on Recurring Basis, Unobservable Input Reconciliation [Table Text Block]	The following table summarizes the activity for financial assets and liabilities utilizing Level 3 fair value measurements: 2015 2014 Dollars in Millions ARS Written option liabilities Contingent consideration liability ARS Written option liabilities Contingent consideration liability Fair value at January 1 $ 12 $ (198 ) $ (8 ) $ 12 $ (162 ) $ (8 ) Settlements and other — 75 — — — — Changes in fair value — 123 — — (36 ) — Fair value at September 30 $ 12 $ — $ (8 ) $ 12 $ (198 ) $ (8 )
Available-for-sale Securities [Table Text Block]	The following table summarizes available-for-sale securities: Dollars in Millions Amortized Gross Gross Fair Value September 30, 2015 Certificates of deposit $ 263 $ — $ — $ 263 Commercial paper 100 — — 100 Corporate debt securities 5,570 32 (11 ) 5,591 ARS 9 3 — 12 Equity investments 75 7 (14 ) 68 Total $ 6,017 $ 42 $ (25 ) $ 6,034 December 31, 2014 Certificates of deposit $ 896 $ — $ — $ 896 Corporate debt securities 5,237 30 (8 ) 5,259 ARS 9 3 — 12 Equity investments 14 22 — 36 Total $ 6,156 $ 55 $ (8 ) $ 6,203
Schedule of Derivatives and Fair Value [Table Text Block]	The following table summarizes the fair value of outstanding derivatives: September 30, 2015 December 31, 2014 Dollars in Millions Balance Sheet Location Notional Fair Value Notional Fair Value Derivatives designated as hedging instruments: Interest rate swap contracts Other assets $ 1,750 $ 46 $ 847 $ 46 Interest rate swap contracts Other liabilities — — 1,050 (3 ) Forward starting interest rate swap contracts Other assets 500 11 — — Forward starting interest rate swap contracts Other liabilities 250 (9 ) — — Foreign currency forward contracts Prepaid expenses and other 766 47 1,323 106 Foreign currency forward contracts Other assets 60 12 100 12 Foreign currency forward contracts Accrued expenses 770 (9 ) — —
Schedule of Fair Value and Other Adjustments to Long Term Debt [Table Text Block]	Long-term debt includes: Dollars in Millions September 30, December 31, Principal Value $ 6,367 $ 6,804 Adjustments to Principal Value: Fair value of interest rate swap contracts 46 43 Unamortized basis adjustment from interest rate swap contract terminations 277 454 Unamortized bond discounts (58 ) (59 ) Total $ 6,632 $ 7,242
Schedule of Note Issuances [Table Text Block]	The following table summarizes the note issuances: Amounts in Millions Euro U.S. dollars Principal Value: 1.000% Euro Notes due 2025 € 575 $ 643 1.750% Euro Notes due 2035 575 643 Total € 1,150 $ 1,286 Proceeds net of discount and deferred loan issuance costs € 1,133 $ 1,268 Forward starting interest rate swap contracts terminated: Notional amount € 500 $ 559 Unrealized loss (16 ) (18 )
Schedule of Debt Repurchases [Table Text Block]	Debt redemption activity was as follows: Nine Months Ended September 30, Dollars in Millions 2015 2014 Principal amount $ 1,624 $ 582 Carrying value 1,795 633 Debt redemption price 1,957 676 Notional amount of interest rate swap contracts terminated 735 500 Interest rate swap contract termination payments 11 4 Loss on debt redemption (a) 180 45 (a) Including acceleration of debt issuance costs, loss on interest rate lock contract and other related fees.

RECEIVABLES (Tables)

RECEIVABLES (Tables)	9 Months Ended
	Sep. 30, 2015
Accounts Receivable, Net [Abstract]
Schedule Of Receivables [Table Text Block]	Dollars in Millions September 30, December 31, Trade receivables $ 2,844 $ 2,193 Less allowances (130 ) (93 ) Net trade receivables 2,714 2,100 Alliance receivables 838 888 Prepaid and refundable income taxes 175 178 Other 181 224 Receivables $ 3,908 $ 3,390

INVENTORIES (Tables)

INVENTORIES (Tables)	9 Months Ended
	Sep. 30, 2015
Inventory, Net [Abstract]
Inventories [Table Text Block]	Dollars in Millions September 30, December 31, Finished goods $ 355 $ 500 Work in process 561 856 Raw and packaging materials 214 204 Inventories $ 1,130 $ 1,560

PROPERTY, PLANT AND EQUIPMENT (

PROPERTY, PLANT AND EQUIPMENT (Tables)	9 Months Ended
	Sep. 30, 2015
Property, Plant and Equipment [Abstract]
Property, Plant and Equipment [Table Text Block]	Dollars in Millions September 30, December 31, Land $ 107 $ 109 Buildings 4,442 4,830 Machinery, equipment and fixtures 3,313 3,774 Construction in progress 605 353 Gross property, plant and equipment 8,467 9,066 Less accumulated depreciation (4,218 ) (4,649 ) Property, plant and equipment $ 4,249 $ 4,417

OTHER INTANGIBLE ASSETS (Tables

OTHER INTANGIBLE ASSETS (Tables)	9 Months Ended
	Sep. 30, 2015
Goodwill and Intangible Assets Disclosure [Abstract]
Schedule Of Intangible Assets By Major Class [Table Text Block]	Dollars in Millions September 30, December 31, Licenses $ 534 $ 1,090 Developed technology rights 2,357 2,358 Capitalized software 1,292 1,254 In-process research and development (IPRD) 280 280 Gross other intangible assets 4,463 4,982 Less accumulated amortization (2,919 ) (3,229 ) Total other intangible assets $ 1,544 $ 1,753

DEFERRED INCOME (Tables)

DEFERRED INCOME (Tables)	9 Months Ended
	Sep. 30, 2015
Deferred Revenue Disclosure [Abstract]
Deferred Revenue By Arrangement Disclosure [Table Text Block]	Dollars in Millions September 30, December 31, Alliances (Note 3) $ 1,495 $ 1,493 Gain on sale-leaseback transactions 31 45 Other 67 399 Total deferred income $ 1,593 $ 1,937 Current portion $ 963 $ 1,167 Non-current portion 630 770

EQUITY (Tables)

EQUITY (Tables)	9 Months Ended
	Sep. 30, 2015
Equity [Abstract]
Schedule of Stock by Class [Table Text Block]	Common Stock Capital in Excess of Par Value of Stock Retained Earnings Treasury Stock Noncontrolling Interest Dollars and Shares in Millions Shares Par Value Shares Cost Balance at January 1, 2014 2,208 $ 221 $ 1,922 $ 32,952 559 $ (17,800 ) $ 82 Net earnings — — — 1,991 — — 11 Cash dividends declared — — — (1,796 ) — — — Employee stock compensation plans — — (407 ) — (9 ) 646 — Debt conversion — — (16 ) — (1 ) 35 — Distributions — — — — — — (35 ) Balance at September 30, 2014 2,208 $ 221 $ 1,499 $ 33,147 549 $ (17,119 ) $ 58 Balance at January 1, 2015 2,208 $ 221 $ 1,507 $ 32,541 547 $ (16,992 ) $ 131 Net earnings — — — 1,762 — — 73 Cash dividends declared — — — (1,857 ) — — — Employee stock compensation plans — — (94 ) — (7 ) 384 — Debt conversion — — — — — 2 — Distributions — — — — — — (10 ) Balance at September 30, 2015 2,208 $ 221 $ 1,413 $ 32,446 540 $ (16,606 ) $ 194
Schedule of Comprehensive Income Loss [Table Text Block]	The components of other comprehensive income/(loss) were as follows: 2015 2014 Pretax Tax After tax Pretax Tax After tax Three Months Ended September 30, Derivatives qualifying as cash flow hedges: (a) Unrealized gains/(losses) $ (34 ) $ 14 $ (20 ) $ 96 $ (31 ) $ 65 Reclassified to net earnings (39 ) 13 (26 ) (13 ) 5 (8 ) Derivatives qualifying as cash flow hedges (73 ) 27 (46 ) 83 (26 ) 57 Pension and postretirement benefits: Actuarial losses (272 ) 96 (176 ) (679 ) 236 (443 ) Amortization (b) 20 (6 ) 14 26 (8 ) 18 Settlements (c) 48 (17 ) 31 28 (10 ) 18 Pension and postretirement benefits (204 ) 73 (131 ) (625 ) 218 (407 ) Available-for-sale securities (d) (24 ) 8 (16 ) (35 ) 13 (22 ) Foreign currency translation (34 ) 5 (29 ) (8 ) — (8 ) $ (335 ) $ 113 $ (222 ) $ (585 ) $ 205 $ (380 ) Nine Months Ended September 30, Derivatives qualifying as cash flow hedges: (a) Unrealized gains $ 36 $ (16 ) $ 20 $ 77 $ (25 ) $ 52 Reclassified to net earnings (102 ) 33 (69 ) (8 ) 5 (3 ) Derivatives qualifying as cash flow hedges (66 ) 17 (49 ) 69 (20 ) 49 Pension and postretirement benefits: Actuarial gains/(losses) 20 (7 ) 13 (978 ) 339 (639 ) Amortization (b) 67 (21 ) 46 79 (27 ) 52 Curtailments and settlements (c) 111 (39 ) 72 127 (48 ) 79 Pension and postretirement benefits 198 (67 ) 131 (772 ) 264 (508 ) Available-for-sale securities: Unrealized losses (31 ) 9 (22 ) (6 ) — (6 ) Realized gains — — — (1 ) — (1 ) Available-for-sale securities (31 ) 9 (22 ) (7 ) — (7 ) Foreign currency translation (14 ) (16 ) (30 ) 2 — 2 $ 87 $ (57 ) $ 30 $ (708 ) $ 244 $ (464 ) (a) Included in cost of products sold. (b) Included in cost of products sold, research and development, and marketing, selling and administrative expenses. (c) Included in other (income)/expense.
Schedule of Accumulated Other Comprehensive Income Loss [Table Text Block]	The accumulated balances related to each component of other comprehensive loss, net of taxes, were as follows: Dollars in Millions September 30, December 31, 2014 Derivatives qualifying as cash flow hedges $ 36 $ 85 Pension and other postretirement benefits (2,050 ) (2,181 ) Available-for-sale securities 9 31 Foreign currency translation (390 ) (360 ) Accumulated other comprehensive loss $ (2,395 ) $ (2,425 )

PENSION AND POSTRETIREMENT BE42

PENSION AND POSTRETIREMENT BENEFIT PLANS (Tables)	9 Months Ended
	Sep. 30, 2015
Compensation and Retirement Disclosure [Abstract]
Schedule of Defined Benefit Plans Disclosures [Table Text Block]	The net periodic benefit cost/(credit) of defined benefit pension and postretirement benefit plans includes: Three Months Ended September 30, Nine Months Ended September 30, Pension Benefits Other Benefits Pension Benefits Other Benefits Dollars in Millions 2015 2014 2015 2014 2015 2014 2015 2014 Service cost – benefits earned during the year $ 6 $ 10 $ 1 $ 1 $ 18 $ 30 $ 3 $ 3 Interest cost on projected benefit obligation 60 76 3 3 181 231 9 10 Expected return on plan assets (102 ) (131 ) (7 ) (7 ) (307 ) (395 ) (20 ) (21 ) Amortization of prior service credits — (1 ) (1 ) — (2 ) (3 ) (4 ) (1 ) Amortization of net actuarial (gain)/loss 20 29 1 (2 ) 70 85 3 (2 ) Curtailments and settlements 48 28 — — 111 127 — (3 ) Special termination benefits — — — — — 13 — — Net periodic benefit cost/(credit) $ 32 $ 11 $ (3 ) $ (5 ) $ 71 $ 88 $ (9 ) $ (14 )

EMPLOYEE STOCK BENEFIT PLANS (T

EMPLOYEE STOCK BENEFIT PLANS (Tables)	9 Months Ended
	Sep. 30, 2015
Disclosure of Compensation Related Costs, Share-based Payments [Abstract]
Schedule Of Share Based Compensation Expense [Table Text Block]	Stock-based compensation expense was as follows: Three Months Ended September 30, Nine Months Ended September 30, Dollars in Millions 2015 2014 2015 2014 Restricted stock $ 20 $ 18 $ 62 $ 56 Market share units 9 9 27 25 Performance share units 34 21 87 66 Total stock-based compensation expense $ 63 $ 48 $ 176 $ 147 Income tax benefit $ 20 $ 16 $ 58 $ 49

BUSINESS SEGMENT INFORMATION (N

BUSINESS SEGMENT INFORMATION (Net Sales of Key Products) (Details) - USD ($) $ in Millions	3 Months Ended		9 Months Ended
	Sep. 30, 2015	Sep. 30, 2014	Sep. 30, 2015	Sep. 30, 2014
Segment Reporting Information [Line Items]
Total revenues	$ 4,069	$ 3,921	$ 12,273	$ 11,621
Alliance and other revenues	517	1,078	2,090	3,201
Baraclude [Member]
Segment Reporting Information [Line Items]
Total revenues	320	325	1,003	1,100
Hepatitis C Franchise [Member]
Segment Reporting Information [Line Items]
Total revenues	402	49	1,145	49
Reyataz Franchise [Member]
Segment Reporting Information [Line Items]
Total revenues	270	338	867	1,044
Sustiva Franchise [Member]
Segment Reporting Information [Line Items]
Total revenues	333	357	940	1,037
Alliance and other revenues	296	309	823	894
Erbitux [Member]
Segment Reporting Information [Line Items]
Total revenues	167	187	501	542
Opdivo [Member]
Segment Reporting Information [Line Items]
Total revenues	305	1	467	1
Sprycel [Member]
Segment Reporting Information [Line Items]
Total revenues	411	385	1,191	1,095
Yervoy [Member]
Segment Reporting Information [Line Items]
Total revenues	240	350	861	942
Abilify [Member]
Segment Reporting Information [Line Items]
Total revenues	46	449	707	1,544
Alliance and other revenues	19	410	597	1,350
Orencia [Member]
Segment Reporting Information [Line Items]
Total revenues	484	444	1,345	1,209
Eliquis [Member]
Segment Reporting Information [Line Items]
Total revenues	466	216	1,258	493
Mature Products And All Other [Member]
Segment Reporting Information [Line Items]
Total revenues	625	820	1,988	2,565
Hepatitis C Franchise - Daklinza [Member]
Segment Reporting Information [Line Items]
Total revenues	330	38	892	38
Hepatitis C Franchise - Sunvepra [Member]
Segment Reporting Information [Line Items]
Total revenues	72	11	253	11
Diabetes Alliance [Member]
Segment Reporting Information [Line Items]
Alliance and other revenues	$ 53	$ 42	$ 171	$ 248

ALLIANCES AND COLLABORATIONS (N

ALLIANCES AND COLLABORATIONS (Narrative) (Details) - USD ($) $ in Millions	3 Months Ended		9 Months Ended		12 Months Ended
	Sep. 30, 2015	Sep. 30, 2014	Sep. 30, 2015	Sep. 30, 2014	Dec. 31, 2015	Dec. 31, 2018	Dec. 31, 2017	Dec. 31, 2016	Dec. 31, 2014
Alliances and Collaborations Statement [Line Items]
Net product sales	$ 3,552	$ 2,843	$ 10,183	$ 8,420
Alliance and other revenues	517	1,078	2,090	3,201
Total revenues	4,069	3,921	12,273	11,621
Receivables - from alliance partners	838		838						$ 888
Deferred income from alliances	1,593		1,593						1,937
Upfront payments for licensing and alliance agreements	86		266
Proceeds from divestiture of businesses			121
Gain on sale of businesses	208	315	370	567
Contingent and regulatory milestone payments	450		450
Written Option Liabilities [Member]
Alliances and Collaborations Statement [Line Items]
Fair value of the written option									$ 198
Abilify [Member]
Alliances and Collaborations Statement [Line Items]
Alliance and other revenues	19	410	597	1,350
Total revenues	46	449	707	1,544
Eliquis [Member]
Alliances and Collaborations Statement [Line Items]
Total revenues	466	216	1,258	493
Erbitux [Member]
Alliances and Collaborations Statement [Line Items]
Total revenues	$ 167	187	$ 501	542
Otsuka [Member] | United States [Member] | Abilify [Member]
Alliances and Collaborations Statement [Line Items]
Percentage of net sales recognized from collaboration	50.00%		50.00%						33.00%
The Medicines Company [Member]
Alliances and Collaborations Statement [Line Items]
Proceeds from divestiture of businesses			$ 132
Gain on sale of businesses			59
The Medicines Company [Member] | Written Option Liabilities [Member]
Alliances and Collaborations Statement [Line Items]
Fair value of the written option	$ 35		35
Valeant [Member]
Alliances and Collaborations Statement [Line Items]
Proceeds from divestiture of businesses			61
Gain on sale of businesses			88
Valeant [Member] | Written Option Liabilities [Member]
Alliances and Collaborations Statement [Line Items]
Fair value of the written option	34		34
Reckitt Benckiser Group [Member]
Alliances and Collaborations Statement [Line Items]
Credit included in other income related to the decrease in the fair value of a written option	87		123
Alliance Partners [Member]
Alliances and Collaborations Statement [Line Items]
Net product sales	981	816	3,203	2,493
Alliance and other revenues	496	958	2,003	2,909
Total revenues	1,477	1,774	5,206	5,402
Payments to/(from) alliance partners - Cost of products sold	445	338	1,257	1,016
Payments to/(from) alliance partners - Marketing, selling and administrative	(14)	31	(15)	34
Payments to/(from) alliance partners - Advertising and product promotion	18	6	41	73
Payments to/(from) alliance partners - Research and development	89	33	277	13
Payments to/(from) alliance partners - Other (income)/expense	(173)	(411)	(622)	(964)
Noncontrolling interest, pre-tax	17	$ 7	45	$ 18
Receivables - from alliance partners	838		838						$ 888
Accounts payable - to alliance partners	446		446						1,479
Deferred income from alliances	$ 1,495		$ 1,495						$ 1,493
Lilly [Member] | United States [Member] | Erbitux [Member]
Alliances and Collaborations Statement [Line Items]
Collaboration distribution fee percentage	39.00%		39.00%
Divestiture non-cash charge					$ 170
Royalty rate sales threshold - Minimum					165	$ 480	$ 650	$ 650
Royalty rate sales threshold - Maximum					$ 165	$ 480	$ 650	$ 650
Lilly and Merck KGaA [Member] | Japan [Member] | Erbitux [Member]
Alliances and Collaborations Statement [Line Items]
Percentage share of pretax profit from net sales of collaboration	50.00%		50.00%
Promedior [Member]
Alliances and Collaborations Statement [Line Items]
Upfront payments for licensing and alliance agreements	$ 150
Warrant upfront payment	84
Upfront payment capitalized	66		$ 66
Warrant exercise payment based on IPF study			300
Warrant exercise payment based on MF study			250
Contingent and regulatory milestone payments	$ 800		$ 800
Minimum [Member] | Lilly [Member] | United States [Member] | Erbitux [Member]
Alliances and Collaborations Statement [Line Items]
Royalty rate on net sales					20.00%
Maximum [Member] | Lilly [Member] | United States [Member] | Erbitux [Member]
Alliances and Collaborations Statement [Line Items]
Royalty rate on net sales					38.00%

ALLIANCES AND COLLABORATIONS (A

ALLIANCES AND COLLABORATIONS (AstraZeneca) (Details) - USD ($) $ in Millions	3 Months Ended		9 Months Ended		12 Months Ended
	Sep. 30, 2015	Sep. 30, 2014	Sep. 30, 2015	Sep. 30, 2014	Dec. 31, 2019	Dec. 31, 2014
Alliances and Collaborations Statement [Line Items]
Proceeds from divestiture of businesses			$ 121
Percentage of potential future royalties transferred					70.00%
Net product sales	$ 3,552	$ 2,843	10,183	$ 8,420
Alliance and other revenues	517	1,078	2,090	3,201
Total revenues	4,069	3,921	12,273	11,621
Provision for restructuring	10	35	50	72
Gain on sale of business	208	315	370	567
Deferred income - Cash Flow information			153	404
Divestitures and other proceeds			673	3,453
Deferred income	1,593		1,593			$ 1,937
AstraZeneca [Member]
Alliances and Collaborations Statement [Line Items]
Proceeds from divestiture of businesses	179
Net product sales		2	10	163
Alliance and other revenues	53	40	161	85
Total revenues	53	42	171	248
Profit sharing - Cost of products sold		1		78
Payments to/(from) alliance partners - Cost of products sold				(9)
Payments to/(from) alliance partners - Marketing, selling and administrative				(7)
Payments to/(from) alliance partners - Advertising and product promotion				(4)
Payments to/(from) alliance partners - Research and development		(1)		(10)
Provision for restructuring				(2)
Royalties	(28)	(46)	(190)	(184)
Transitional services	(3)	(18)	(8)	(83)
Gain on sale of business	(79)	(292)	(83)	(539)
Deferred income - Cash Flow information	23	19	32	308
Divestitures and other proceeds	251	208	349	3,415
AstraZeneca [Member] | Amortization Income Expense [Member]
Alliances and Collaborations Statement [Line Items]
Amortization of deferred income	(31)	$ (23)	(80)	$ (57)
AstraZeneca [Member] | Assets Not Yet Transferred to Alliance Partner [Member]
Alliances and Collaborations Statement [Line Items]
Deferred income						176
AstraZeneca [Member] | Services Not Yet Performed For Alliance Partner [Member]
Alliances and Collaborations Statement [Line Items]
Deferred income	$ 170		$ 170			$ 226

ACQUISITIONS AND OTHER DIVEST47

ACQUISITIONS AND OTHER DIVESTITURES ACQUISITIONS AND OTHER DIVESTITURES (Details) - USD ($) $ in Millions	3 Months Ended		9 Months Ended
	Sep. 30, 2015	Sep. 30, 2014	Sep. 30, 2015	Sep. 30, 2014	Dec. 31, 2014
Business Combinations [Abstract]
Asset acquisition payment	$ 800		$ 800
Contingent and regulatory milestone payments	450		450
Upfront payment allocated to research and development expenses	800	$ 148	800	$ 148
Deferred tax assets related to acquisition	14		14
Proceeds from divestiture of businesses			121
Gain on divested businesses and product lines			136
Gain on sale of businesses	$ 208	$ 315	$ 370	$ 567
Deferred gain					$ 40

ASSETS HELD-FOR-SALE ASSETS H48

ASSETS HELD-FOR-SALE ASSETS HELD-FOR-SALE (Details) - USD ($) $ in Millions	Sep. 30, 2015	Dec. 31, 2014
ASSETS HELD-FOR-SALE [Abstract]
Inventories	$ 20	$ 38
Property, plant and equipment	14
Goodwill	66	19
Other intangible assets	126	52
Accrued rebates and returns	(11)
Assets held-for-sale, Current	$ 215	$ 109

OTHER (INCOME)_EXPENSE (Details

OTHER (INCOME)/EXPENSE (Details) - USD ($) $ in Millions	3 Months Ended		9 Months Ended
	Sep. 30, 2015	Sep. 30, 2014	Sep. 30, 2015	Sep. 30, 2014
Other Nonoperating Income (Expense) [Abstract]
Interest expense	$ 41	$ 50	$ 141	$ 150
Investment income	(18)	(20)	(74)	(71)
Provision for restructuring	10	35	50	72
Litigation charges/(recoveries)	(2)	10	14	19
Equity in net income of affiliates	(19)	(12)	(67)	(81)
Out-licensed intangible asset impairment		18	13	18
Gain on sale of product lines, businesses and assets	(208)	(315)	(370)	(567)
Other alliance and licensing income	(187)	(102)	(472)	(354)
Pension curtailments, settlements and special termination benefits	48	28	111	137
Loss on debt redemption			180	45
Other	12	31	(41)	43
Other (income)/expense	$ (323)	$ (277)	$ (515)	$ (589)

RESTRUCTURING (Details)

RESTRUCTURING (Details) $ in Millions	3 Months Ended		9 Months Ended
	Sep. 30, 2015USD ($)	Sep. 30, 2014USD ($)	Sep. 30, 2015USD ($)	Sep. 30, 2014USD ($)	Dec. 31, 2015USD ($)
Employee termination benefits	$ 9	$ 34	$ 45	$ 68
Other exit costs	1	1	5	4
Provision for restructuring	$ 10	$ 35	$ 50	$ 72
Workforce reduction of manufacturing, selling, administrative, and research and development personnel	60	360	685	760
Restructuring expected cost					$ 100
Liability at January 1			$ 156	$ 102
Charges			55	79
Change in estimates			(5)	(7)
Foreign currency translation			(11)	(1)
Payments			(100)	(73)
Liability at September 30	$ 95	$ 100	$ 95	$ 100

INCOME TAXES (Details)

INCOME TAXES (Details) - USD ($) $ in Millions	3 Months Ended		9 Months Ended
	Sep. 30, 2015	Sep. 30, 2014	Sep. 30, 2015	Sep. 30, 2014
Significant Change in Unrecognized Tax Benefits is Reasonably Possible [Line Items]
Earnings Before Income Taxes	$ 987	$ 1,008	$ 2,487	$ 2,441
Provision for Income Taxes	$ 257	$ 276	$ 668	$ 439
Effective income tax rate	26.00%	27.40%	26.90%	18.00%
U.S statutory income tax rate			35.00%
Acquisition payment not deductible for tax purposes	$ 800	$ 148	$ 800	$ 148
Minimum [Member]
Significant Change in Unrecognized Tax Benefits is Reasonably Possible [Line Items]
Estimated decrease in total amount of unrecognized tax benefits	280		280
Maximum [Member]
Significant Change in Unrecognized Tax Benefits is Reasonably Possible [Line Items]
Estimated decrease in total amount of unrecognized tax benefits	$ 340		$ 340

EARNINGS_(LOSS) PER SHARE (Deta

EARNINGS/(LOSS) PER SHARE (Details) - USD ($) $ / shares in Units, shares in Millions, $ in Millions	3 Months Ended		9 Months Ended
	Sep. 30, 2015	Sep. 30, 2014	Sep. 30, 2015	Sep. 30, 2014
Earnings Per Share [Abstract]
Net earnings attributable to BMS used for Basic and Diluted EPS Calculation	$ 706	$ 721	$ 1,762	$ 1,991
Weighted-average common shares outstanding - basic	1,668	1,658	1,666	1,656
Contingently convertible debt common stock equivalents		1		1
Incremental shares attributable to share-based compensation plans	10	11	11	11
Weighted-average common shares outstanding - diluted	1,678	1,670	1,677	1,668
Earnings per share - basic	$ 0.42	$ 0.43	$ 1.06	$ 1.20
Earnings per share - diluted	$ 0.42	$ 0.43	$ 1.05	$ 1.19

FINANCIAL INSTRUMENTS AND FAI53

FINANCIAL INSTRUMENTS AND FAIR VALUE MEASUREMENTS (Fair Value Measurement) (Details) - USD ($) $ in Millions	9 Months Ended
	Sep. 30, 2015	Sep. 30, 2014	Dec. 31, 2014
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Cash and Cash Equivalents, Fair Value Disclosure	$ 3,435		$ 5,051
Available-for-sale Securities	6,034		6,203
Certificates of Deposit [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Available-for-sale Securities	263		896
Commercial Paper [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Available-for-sale Securities	100
Corporate Debt Securities [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Available-for-sale Securities	5,591		5,259
Equity Funds [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Other Marketable Securities, Current	88		94
Fixed Income Funds [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Other Marketable Securities, Current	11		11
Auction Rate Securities [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Available-for-sale Securities	12		12
Fair Value, Assets Measured on Recurring Basis, Unobservable Input Reconciliation, Calculation [Roll Forward]
Fair value at January 1, Asset	12	$ 12
Fair value at September 30, Asset	12	12
Equity Investments [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Available-for-sale Securities	68		36
Written Option Liabilities [Member]
Fair Value, Assets Measured on Recurring Basis, Unobservable Input Reconciliation, Calculation [Roll Forward]
Fair Value at January 1, Liability	(198)	(162)
Settlements and other	75
Changes in fair value	123	(36)
Fair Value at September 30, Liability		(198)
Contingent Consideration Liability [Member]
Fair Value, Assets Measured on Recurring Basis, Unobservable Input Reconciliation, Calculation [Roll Forward]
Fair Value at January 1, Liability	(8)	(8)
Fair Value at September 30, Liability	(8)	$ (8)
Interest Rate Swap Contracts [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Derivative asset	46		46
Derivative liabilities			(3)
Forward Starting Interest Rate Swap Contracts [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Derivative asset	11
Derivative liabilities	(9)
Foreign Currency Forward Contracts [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Derivative asset	59		118
Derivative liabilities	(9)
Written Option Liabilities [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Derivative liabilities			(198)
Contingent Consideration Liability [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Derivative liabilities	(8)		(8)
Fair Value, Inputs, Level 1 [Member] | Equity Investments [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Available-for-sale Securities	68		36
Fair Value, Inputs, Level 2 [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Cash and Cash Equivalents, Fair Value Disclosure	3,435		5,051
Fair Value, Inputs, Level 2 [Member] | Certificates of Deposit [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Available-for-sale Securities	263		896
Fair Value, Inputs, Level 2 [Member] | Commercial Paper [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Available-for-sale Securities	100
Fair Value, Inputs, Level 2 [Member] | Corporate Debt Securities [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Available-for-sale Securities	5,591		5,259
Fair Value, Inputs, Level 2 [Member] | Equity Funds [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Other Marketable Securities, Current	88		94
Fair Value, Inputs, Level 2 [Member] | Fixed Income Funds [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Other Marketable Securities, Current	11		11
Fair Value, Inputs, Level 2 [Member] | Interest Rate Swap Contracts [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Derivative asset	46		46
Derivative liabilities			(3)
Fair Value, Inputs, Level 2 [Member] | Forward Starting Interest Rate Swap Contracts [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Derivative asset	11
Derivative liabilities	(9)
Fair Value, Inputs, Level 2 [Member] | Foreign Currency Forward Contracts [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Derivative asset	59		118
Derivative liabilities	(9)
Fair Value, Inputs, Level 3 [Member] | Auction Rate Securities [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Available-for-sale Securities	12		12
Fair Value, Inputs, Level 3 [Member] | Written Option Liabilities [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Derivative liabilities			(198)
Fair Value, Inputs, Level 3 [Member] | Contingent Consideration Liability [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Derivative liabilities	$ (8)		$ (8)

FINANCIAL INSTRUMENTS AND FAI54

FINANCIAL INSTRUMENTS AND FAIR VALUE MEASUREMENTS (Available-for-sale) (Details) - USD ($) $ in Millions	Sep. 30, 2015	Dec. 31, 2014
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Marketable Securities, Amortized Cost	$ 6,017	$ 6,156
Marketable Securities, Gross Unrealized Gain in Accumulated OCI	42	55
Marketable Securities, Gross Unrealized Loss in Accumulated OCI	(25)	(8)
Available-for-sale Securities	6,034	6,203
Available-for-sale Securities, Current	1,339	1,759
Certificates of Deposit [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Marketable Securities, Amortized Cost	263	896
Available-for-sale Securities	263	896
Commercial Paper [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Marketable Securities, Amortized Cost	100
Available-for-sale Securities	100
Corporate Debt Securities [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Marketable Securities, Amortized Cost	5,570	5,237
Marketable Securities, Gross Unrealized Gain in Accumulated OCI	32	30
Marketable Securities, Gross Unrealized Loss in Accumulated OCI	(11)	(8)
Available-for-sale Securities	5,591	5,259
Auction Rate Securities [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Marketable Securities, Amortized Cost	9	9
Marketable Securities, Gross Unrealized Gain in Accumulated OCI	3	3
Available-for-sale Securities	12	12
Equity Investments [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Marketable Securities, Amortized Cost	75	14
Marketable Securities, Gross Unrealized Gain in Accumulated OCI	7	22
Marketable Securities, Gross Unrealized Loss in Accumulated OCI	(14)
Available-for-sale Securities	68	$ 36
Other Assets [Member] | Equity Investments [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Available-for-sale Securities, Noncurrent	$ 68

FINANCIAL INSTRUMENTS AND FAI55

FINANCIAL INSTRUMENTS AND FAIR VALUE MEASUREMENTS (Derivatives and Hedging) (Details) € in Millions, $ in Millions	9 Months Ended
	Sep. 30, 2015USD ($)	Sep. 30, 2015EUR (€)	Sep. 30, 2015USD ($)	Dec. 31, 2014USD ($)
Derivative [Line Items]
Notional amount of U.S. dollar interest rate contracts maturing March 2017			$ 750
Period, in years, of reclassification to earnings, cash flow hedges	2
The period, in days, after a forecasted transaction after which cash flow hedge accounting is discontinued	60
Notional amount of nonderivative instruments designated as net investment hedges		€ 950	1,064
Notional amount of terminated interest rate swaps	$ 147
Proceeds from terminated interest rate swaps including accrued interest	28
Proceeds from terminated interest rate swaps accrued interest	$ 1
Interest Rate Swap Contracts [Member]
Derivative [Line Items]
Derivative asset			46	$ 46
Total derivatives at fair value, liabilities				(3)
Interest Rate Swap Contracts [Member] | Fair Value, Inputs, Level 2 [Member]
Derivative [Line Items]
Derivative asset			46	46
Total derivatives at fair value, liabilities				(3)
Interest Rate Swap Contracts [Member] | Designated as Hedging Instrument [Member] | Other Assets [Member]
Derivative [Line Items]
Notional amount of derivatives			1,750	847
Derivative asset			46	46
Interest Rate Swap Contracts [Member] | Designated as Hedging Instrument [Member] | Other Noncurrent Liabilities [Member]
Derivative [Line Items]
Notional amount of derivatives				1,050
Total derivatives at fair value, liabilities				(3)
Forward Starting Interest Rate Swap Contracts [Member]
Derivative [Line Items]
Derivative asset			11
Total derivatives at fair value, liabilities			(9)
Forward Starting Interest Rate Swap Contracts [Member] | Fair Value, Inputs, Level 2 [Member]
Derivative [Line Items]
Derivative asset			11
Total derivatives at fair value, liabilities			(9)
Forward Starting Interest Rate Swap Contracts [Member] | Designated as Hedging Instrument [Member] | Other Assets [Member]
Derivative [Line Items]
Notional amount of derivatives			500
Derivative asset			11
Forward Starting Interest Rate Swap Contracts [Member] | Designated as Hedging Instrument [Member] | Other Noncurrent Liabilities [Member]
Derivative [Line Items]
Notional amount of derivatives			250
Total derivatives at fair value, liabilities			(9)
Foreign Currency Forward Contracts [Member]
Derivative [Line Items]
Derivative asset			59	118
Total derivatives at fair value, liabilities			(9)
Foreign Currency Forward Contracts [Member] | Fair Value, Inputs, Level 2 [Member]
Derivative [Line Items]
Derivative asset			59	118
Total derivatives at fair value, liabilities			(9)
Foreign Currency Forward Contracts [Member] | Designated as Hedging Instrument [Member] | Other Assets [Member]
Derivative [Line Items]
Notional amount of derivatives			60	100
Derivative asset			12	12
Foreign Currency Forward Contracts [Member] | Designated as Hedging Instrument [Member] | Prepaid Expenses and Other Current Assets [Member]
Derivative [Line Items]
Notional amount of derivatives			766	1,323
Derivative asset			47	$ 106
Foreign Currency Forward Contracts [Member] | Designated as Hedging Instrument [Member] | Accrued expenses [Member]
Derivative [Line Items]
Notional amount of derivatives			770
Total derivatives at fair value, liabilities			(9)
Euro Member Countries, Euro | Cash Flow Hedging [Member]
Derivative [Line Items]
Notional amount of derivatives			478
Japan, Yen | Foreign Currency Forward Contracts [Member] | Not Designated as Hedging Instrument [Member] | Accrued expenses [Member]
Derivative [Line Items]
Notional amount of derivatives			445
Total derivatives at fair value, liabilities			2
Japan, Yen | Cash Flow Hedging [Member]
Derivative [Line Items]
Notional amount of derivatives			$ 734

FINANCIAL INSTRUMENTS AND FAI56

FINANCIAL INSTRUMENTS AND FAIR VALUE MEASUREMENTS (Debt) (Details) - USD ($) $ in Millions	9 Months Ended
	Sep. 30, 2015	Sep. 30, 2014	Dec. 31, 2014
Debt Instrument [Line Items]
Principal value	$ 6,367		$ 6,804
Adjustments to Principal Value, Fair value of interest rate swaps	46		43
Adjustments to Principal Value, Unamortized basis adjustment from swap terminations	277		454
Adjustments to Principal Value, Unamortized bond discounts	(58)		(59)
Total Long-term debt	6,632		7,242
Long-term debt	6,632		7,242
Long-term debt, fair value	6,935		$ 8,045
Interest payments	158	$ 131
Proceeds from issuance of long-term debt	1,268
Extinguishment of Debt, Principal Value	1,624	582
Extinguishment Of Debt, Carrying Value	1,795	633
Extinguishment of Debt, Redemption Price	1,957	676
Extinguishment of Debt, Notional amount of interest rate swaps terminated	735	500
Extinguishment of Debt, Swap Termination Payments	11	4
Extinguishment of Debt, Total loss	180	$ 45
Euro Member Countries, Euro
Debt Instrument [Line Items]
Principal value	1,150
Proceeds from issuance of long-term debt	1,133
Extinguishment of Debt, Principal Value	1,000
Euro Member Countries, Euro | 1.000% Euro Notes Due 2025 [Member]
Debt Instrument [Line Items]
Principal value	575
Euro Member Countries, Euro | 1.750% Euro Notes Due 2035 [Member]
Debt Instrument [Line Items]
Principal value	575
United States of America, Dollars
Debt Instrument [Line Items]
Principal value	1,286
Proceeds from issuance of long-term debt	1,268
Long-term Debt Repurchased Through Cash Tender Offer	500
Extinguishment of Debt, Principal Value	1,100
United States of America, Dollars | 1.000% Euro Notes Due 2025 [Member]
Debt Instrument [Line Items]
Principal value	643
United States of America, Dollars | 1.750% Euro Notes Due 2035 [Member]
Debt Instrument [Line Items]
Principal value	643
Forward Starting Interest Rate Swap Contracts [Member] | Euro Member Countries, Euro
Debt Instrument [Line Items]
Notional amount of forward starting interest rate swap contracts terminated	500
Unrealized loss of terminated forward starting interest rate swap contracts	(16)
Forward Starting Interest Rate Swap Contracts [Member] | United States of America, Dollars
Debt Instrument [Line Items]
Notional amount of forward starting interest rate swap contracts terminated	559
Unrealized loss of terminated forward starting interest rate swap contracts	$ (18)

RECEIVABLES (Details)

RECEIVABLES (Details) $ in Millions	9 Months Ended
	Sep. 30, 2015USD ($)	Sep. 30, 2014USD ($)	Dec. 31, 2014USD ($)
Accounts, Notes, Loans and Financing Receivable [Line Items]
Trade receivables	$ 2,844		$ 2,193
Less allowances	(130)		(93)
Net trade receivables	2,714		2,100
Alliance receivables	838		888
Prepaid and refundable income taxes	175		178
Other receivables	181		224
Receivables	3,908		$ 3,390
Non-U.S. receivables sold on a nonrecourse basis	$ 327	$ 684
Percent of aggregate total trade receivables due from three pharmaceutical wholesalers	45.00%		36.00%
Number Of Largest Pharmaceutical Wholesalers	3

INVENTORIES (Details)

INVENTORIES (Details) - USD ($) $ in Millions	Sep. 30, 2015	Dec. 31, 2014
Inventory, Net [Abstract]
Finished goods	$ 355	$ 500
Work in process	561	856
Raw and packaging materials	214	204
Inventories	1,130	1,560
Inventory pending regulatory approval	77
Inventories expected to remain on-hand beyond one year and included in other assets	$ 277	$ 232

PROPERTY, PLANT AND EQUIPMENT59

PROPERTY, PLANT AND EQUIPMENT (Details) - USD ($) $ in Millions	9 Months Ended
	Sep. 30, 2015	Sep. 30, 2014	Aug. 31, 2015	Dec. 31, 2014
Property, Plant and Equipment [Line Items]
Gross property, plant and equipment	$ 8,467			$ 9,066
Less accumulated depreciation	(4,218)			(4,649)
Property, plant and equipment	4,249			4,417
Depreciation expense	393	$ 412
Land [Member]
Property, Plant and Equipment [Line Items]
Gross property, plant and equipment	107			109
Buildings [Member]
Property, Plant and Equipment [Line Items]
Gross property, plant and equipment	4,442			4,830
Machinery, equipment and fixtures [Member]
Property, Plant and Equipment [Line Items]
Gross property, plant and equipment	3,313			3,774
Mount Vernon Facility [Member]
Property, Plant and Equipment [Line Items]
Gross property, plant and equipment			$ 415
Property, plant and equipment			$ 182
Manufacturing Facility [Member]
Property, Plant and Equipment [Line Items]
Less accumulated depreciation	(369)
Construction in Progress [Member]
Property, Plant and Equipment [Line Items]
Gross property, plant and equipment	$ 605			$ 353

OTHER INTANGIBLE ASSETS (Detail

OTHER INTANGIBLE ASSETS (Details) - USD ($) $ in Millions	9 Months Ended
	Sep. 30, 2015	Sep. 30, 2014	Dec. 31, 2014
Acquired Finite-Lived Intangible Assets [Line Items]
In-process research and development	$ 280		$ 280
Gross other intangible assets	4,463		4,982
Less: accumulated amortization	(2,919)		(3,229)
Other intangible assets	1,544		1,753
Other intangible assets held-for-sale, gross	500
Other intangible assets held-for-sale, net	126		52
Amortization expense	140	$ 222
Licensing Agreements [Member]
Acquired Finite-Lived Intangible Assets [Line Items]
Finite-lived intangible assets	534		1,090
Developed Technology Rights [Member]
Acquired Finite-Lived Intangible Assets [Line Items]
Finite-lived intangible assets	2,357		2,358
Capitalized Software, Intangible Asset [Member]
Acquired Finite-Lived Intangible Assets [Line Items]
Finite-lived intangible assets	$ 1,292		$ 1,254

DEFERRED INCOME (Details)

DEFERRED INCOME (Details) - USD ($) $ in Millions	9 Months Ended
	Sep. 30, 2015	Sep. 30, 2014	Dec. 31, 2014
Deferred Revenue Disclosure [Abstract]
Alliances	$ 1,495		$ 1,493
Gain on sale-leaseback transactions	31		45
Other	67		399
Total deferred income	1,593		1,937
Deferred income current	963		1,167
Deferred income non-current	630		770
Early access program			$ 300
Amortization of deferred income	$ 233	$ 270

EQUITY (Changes in Equity) (Det

EQUITY (Changes in Equity) (Details) - USD ($) shares in Millions, $ in Millions	3 Months Ended		9 Months Ended
	Sep. 30, 2015	Sep. 30, 2014	Sep. 30, 2015	Sep. 30, 2014
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Common Stock, Value, Issued, Balance at January 1,			$ 221
Common Stock, Value, Issued, Balance at September 30,	$ 221		221
Capital in Excess of Par Value of Stock, Balance at January 1,			1,507
Capital in Excess of Par Value of Stock, Balance at September 30,	1,413		1,413
Retained Earnings, Balance at January 1,			32,541
Net Earnings Attributable to BMS	706	$ 721	1,762	$ 1,991
Retained Earnings, Balance at September 30,	$ 32,446		$ 32,446
Treasury Stock, Shares, Balance at January 1,			547
Treasury Stock, Shares, Balance at September 30,	540		540
Cost of Treasury Stock, Balance at January 1,			$ (16,992)
Cost of Treasury Stock, Balance at September 30,	$ (16,606)		(16,606)
Noncontrolling interest, Balance at January 1,			131
Noncontrolling interest, Balance at September 30,	$ 194		$ 194
Common Stock [Member]
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Common Stock, Shares Issued, Balance at January 1,			2,208	2,208
Common Stock, Shares Issued, Balance at September 30,	2,208	2,208	2,208	2,208
Common Stock, Value, Issued, Balance at January 1,			$ 221	$ 221
Common Stock, Value, Issued, Balance at September 30,	$ 221	$ 221	221	221
Capital in Excess of Par Value of Stock [Member]
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Capital in Excess of Par Value of Stock, Balance at January 1,			1,507	1,922
Employee stock compensation plans, Capital in Excess of Par			(94)	(407)
Debt Conversion, Capital in Excess of Par Value of Stock				(16)
Capital in Excess of Par Value of Stock, Balance at September 30,	1,413	1,499	1,413	1,499
Retained Earnings [Member]
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Retained Earnings, Balance at January 1,			32,541	32,952
Net Earnings Attributable to BMS			1,762	1,991
Cash dividends declared			(1,857)	(1,796)
Retained Earnings, Balance at September 30,	$ 32,446	$ 33,147	$ 32,446	$ 33,147
Treasury Stock [Member]
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Treasury Stock, Shares, Balance at January 1,			547	559
Employee stock compensation plans, Shares			(7)	(9)
Debt conversion, Shares				(1)
Treasury Stock, Shares, Balance at September 30,	540	549	540	549
Cost of Treasury Stock, Balance at January 1,			$ (16,992)	$ (17,800)
Employee stock compensation plans, Cost			384	646
Debt conversion, cost			2	35
Cost of Treasury Stock, Balance at September 30,	$ (16,606)	$ (17,119)	(16,606)	(17,119)
Noncontrolling Interest [Member]
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Noncontrolling interest, Balance at January 1,			131	82
Net earnings attributable to noncontrolling interest			73	11
Distributions			(10)	(35)
Noncontrolling interest, Balance at September 30,	$ 194	$ 58	$ 194	$ 58

EQUITY (Other Comprehensive Inc

EQUITY (Other Comprehensive Income/(Loss)) (Details) - USD ($) $ in Millions	3 Months Ended		9 Months Ended
	Sep. 30, 2015	Sep. 30, 2014	Sep. 30, 2015	Sep. 30, 2014	Dec. 31, 2014
Other Comprehensive Income (Loss), before Tax [Abstract]
Derivatives qualifying as cash flow hedges - Unrealized gain/(loss), Pre-tax	$ (34)	$ 96	$ 36	$ 77
Derivatives qualifying as cash flow hedges - Reclassified to net earnings, Pre-tax	(39)	(13)	(102)	(8)
Derivatives qualifying as cash flow hedges, Pre-tax	(73)	83	(66)	69
Pension and postretirement benefits - Actuarial gain/(loss), Pre-tax	(272)	(679)	20	(978)
Pension and postretirement benefits - Amortization, Pre-tax	20	26	67	79
Pension and postretirement benefits - Curtailments and settlements, Pre-Tax	48	28	111	127
Pension and postretirement benefits, Pre-tax	(204)	(625)	198	(772)
Other Comprehensive Income (Loss), Unrealized holding gain/(loss) on securities arising during period, before Tax			(31)	(6)
Other Comprehensive Income (Loss), Reclassification adjustment from AOCI for sale of securities, before Tax				(1)
Available-for-sale securities, Pre-tax	(24)	(35)	(31)	(7)
Foreign currency translation, Pre-tax	(34)	(8)	(14)	2
Other Comprehensive Income/(Loss), Pre-tax	(335)	(585)	87	(708)
Other Comprehensive Income (Loss), Tax, Parenthetical Disclosures [Abstract]
Derivatives qualifying as cash flow hedges - Unrealized gain/(loss), Tax	14	(31)	(16)	(25)
Derivatives qualifying as cash flow hedges - Reclassified to net earnings, Tax	13	5	33	5
Derivatives qualifying as cash flow hedges, Tax	27	(26)	17	(20)
Pension and postretirement benefits - Actuarial gain/(loss), Tax	96	236	(7)	339
Pension and postretirement benefits - Amortization, Tax	(6)	(8)	(21)	(27)
Pension and postretirement benefits - Curtailments and settlements, Tax	(17)	(10)	(39)	(48)
Pension and postretirement benefits, Tax	73	218	(67)	264
Other Comprehensive Income (Loss), Unrealized holding gain/(loss) on securities arising during period, Tax			9
Available-for-sale securities, Tax	8	13	9
Other Comprehensive Income (Loss), Foreign Currency Translation Adjustment, Tax	5		(16)
Other comprehensive income/(loss), Tax	113	205	(57)	244
Other Comprehensive Income (Loss), Net of Tax [Abstract]
Derivatives qualifying as cash flow hedges - Unrealized gain/(loss), After tax	(20)	65	20	52
Derivatives qualifying as cash flow hedges - Reclassified to net earnings, After tax	(26)	(8)	(69)	(3)
Derivatives qualifying as cash flow hedges, After tax	(46)	57	(49)	49
Pension and postretirement benefits - Actuarial gain/(loss), After tax	(176)	(443)	13	(639)
Pension and postretirement benefits - Amortization, After tax	14	18	46	52
Pension and postretirement benefits - Curtailments and settlements, After tax	31	18	72	79
Pension and postretirement benefits, After tax	(131)	(407)	131	(508)
Other Comprehensive Income (Loss), Unrealized holding gain/(loss) on securities arising during period, After tax			(22)	(6)
Other Comprehensive Income (Loss), Reclassification adjustment from AOCI for sale of securities, After tax				(1)
Available-for-sale securities, After tax	(16)	(22)	(22)	(7)
Foreign currency translation, After tax	(29)	(8)	(30)	2
Other Comprehensive Income/(Loss)	(222)	$ (380)	30	$ (464)
Derivatives qualifying as cash flow hedges	36		36		$ 85
Pension and postretirement benefits	(2,050)		(2,050)		(2,181)
Available-for-sale securities	9		9		31
Foreign currency translation	(390)		(390)		(360)
Accumulated other comprehensive loss	$ (2,395)		$ (2,395)		$ (2,425)

PENSION AND POSTRETIREMENT BE64

PENSION AND POSTRETIREMENT BENEFIT PLANS (Details) - USD ($) $ in Millions	3 Months Ended		9 Months Ended		12 Months Ended
	Sep. 30, 2015	Sep. 30, 2014	Sep. 30, 2015	Sep. 30, 2014	Dec. 31, 2015	Dec. 31, 2014
Pension, Postretirement And Postemployment Liabilities Statement [Line Items]
Decrease to liabilities and a corresponding decrease in accumulated other comprehensive loss	$ 272	$ 679	$ (20)	$ 978
Weighted average discount rate assumed in remeasuring the pension benefit obligations			4.20%			3.80%
Defined contribution plan expense	53	45	$ 142	141
Pension Benefits [Member]
Pension, Postretirement And Postemployment Liabilities Statement [Line Items]
Service cost - benefits earned during the period	6	10	18	30
Interest cost on projected benefit obligation	60	76	181	231
Expected return on plan assets	(102)	(131)	(307)	(395)
Amortization of prior service credits		(1)	(2)	(3)
Amortization of net actuarial (gain)/loss	20	29	70	85
Pension curtailments and settlements	48	28	111	127
Special termination benefits				13
Net periodic benefit cost/(credit)	32	11	71	88
Expected contributions to pension plans					$ 100
Contributions to pension plan			79
Other Benefits [Member]
Pension, Postretirement And Postemployment Liabilities Statement [Line Items]
Service cost - benefits earned during the period	1	1	3	3
Interest cost on projected benefit obligation	3	3	9	10
Expected return on plan assets	(7)	(7)	(20)	(21)
Amortization of prior service credits	(1)		(4)	(1)
Amortization of net actuarial (gain)/loss	1	(2)	3	(2)
Pension curtailments and settlements				(3)
Net periodic benefit cost/(credit)	$ (3)	$ (5)	$ (9)	$ (14)

EMPLOYEE STOCK BENEFIT PLANS (D

EMPLOYEE STOCK BENEFIT PLANS (Details) - USD ($) $ / shares in Units, shares in Millions, $ in Millions	3 Months Ended		9 Months Ended
	Sep. 30, 2015	Sep. 30, 2014	Sep. 30, 2015	Sep. 30, 2014
Employee Service Share Based Compensation Allocation Of Recognized Period Costs [Line Items]
Total stock-based compensation expense	$ 63	$ 48	$ 176	$ 147
Income tax benefit	20	16	58	49
Unrecognized compensation cost	364		$ 364
Weighted-average period over which unrecognized compensation cost is expected to be recognized			2 years 4 months 24 days
Restricted Stock [Member]
Employee Service Share Based Compensation Allocation Of Recognized Period Costs [Line Items]
Total stock-based compensation expense	20	18	$ 62	56
Number of shares granted			1.7
Weighted average grant date fair value of grants during the period			$ 61.20
Share-based compensation arrangement by share-based payment award, award vesting period			4 years
Market share units [Member]
Employee Service Share Based Compensation Allocation Of Recognized Period Costs [Line Items]
Total stock-based compensation expense	9	9	$ 27	25
Number of shares granted			0.7
Weighted average grant date fair value of grants during the period			$ 67.03
Share-based compensation arrangement by share-based payment award, award vesting period			4 years
Performance share units [Member]
Employee Service Share Based Compensation Allocation Of Recognized Period Costs [Line Items]
Total stock-based compensation expense	$ 34	$ 21	$ 87	$ 66
Number of shares granted			1.6
Weighted average grant date fair value of grants during the period			$ 65.07
Share-based compensation arrangement by share-based payment award, award vesting period			3 years

LEGAL PROCEEDINGS AND CONTING66

LEGAL PROCEEDINGS AND CONTINGENCIES (Details) $ in Millions	3 Months Ended		9 Months Ended		12 Months Ended
	Sep. 30, 2015USD ($)lawsuits	Sep. 30, 2014USD ($)	Sep. 30, 2015USD ($)lawsuits	Sep. 30, 2014USD ($)	Dec. 31, 2014USD ($)
Legal Proceedings And Contingencies [Line Items]
Total revenues	$ 4,069	$ 3,921	$ 12,273	$ 11,621
Baraclude [Member]
Legal Proceedings And Contingencies [Line Items]
Total revenues	$ 320	$ 325	1,003	$ 1,100
Baraclude Intellectual Property Litigation [Member] | Baraclude [Member] | South Korea [Member]
Legal Proceedings And Contingencies [Line Items]
Total revenues			$ 99		$ 158
AWP Litigation [Member]
Legal Proceedings And Contingencies [Line Items]
Number of lawsuits | lawsuits	2		2
Loss contingency, Estimate of possible loss	$ 28		$ 28
Qui Tam Litigation [Member]
Legal Proceedings And Contingencies [Line Items]
Number of sales representatives	3		3
Plavix Product Liability Litigation [Member]
Legal Proceedings And Contingencies [Line Items]
Number of lawsuits	5,200		5,200
Reglan Product Liability [Member]
Legal Proceedings And Contingencies [Line Items]
Number of current plaintiffs	3,000		3,000
Byetta Product Liability Litigation [Member]
Legal Proceedings And Contingencies [Line Items]
Number of lawsuits	500		500
Number of plaintiffs settled	510		510
Number of current plaintiffs	2,400		2,400
FCPA Investigation [Member]
Legal Proceedings And Contingencies [Line Items]
Litigation settlement, Gross			$ 14.7
Environmental Proceedings Cercla Matters [Member]
Legal Proceedings And Contingencies [Line Items]
Loss contingency, Estimate of possible loss	$ 61		$ 61
Environmental Proceedings North Brunswick [Member]
Legal Proceedings And Contingencies [Line Items]
Number Of Interim Payments			2
Litigation settlement, Gross			$ 4

SUBSEQUENT EVENTS (Details)

SUBSEQUENT EVENTS (Details) - USD ($) $ in Millions	3 Months Ended	9 Months Ended	12 Months Ended
	Sep. 30, 2015	Sep. 30, 2015	Dec. 31, 2015
Subsequent Event [Line Items]
Upfront And Milestone Payments Made To Collaborative Partner	$ 86	$ 266
Contingent and regulatory milestone payments	$ 450	$ 450
Five Prime [Member]
Subsequent Event [Line Items]
Upfront And Milestone Payments Made To Collaborative Partner			$ 350
Contingent and regulatory milestone payments			$ 1,400